Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Breast Cancer Res Treat
    August 2021
  1. LAISH I, Friedman E, Levi-Reznick G, Kedar I, et al
    Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
    Breast Cancer Res Treat. 2021;188:685-694.
    >> Share

  2. SATO S, Maki S, Yamanaka T, Hoshino D, et al
    Machine learning-based image analysis for accelerating the diagnosis of complicated preneoplastic and neoplastic ductal lesions in breast biopsy tissues.
    Breast Cancer Res Treat. 2021;188:649-659.
    >> Share

  3. WEITZEL JN, Kidd J, Bernhisel R, Shehayeb S, et al
    Multigene assessment of genetic risk for women for two or more breast cancers.
    Breast Cancer Res Treat. 2021;188:759-768.
    >> Share

  4. TANG A, Cohan CM, Hansen KS, Beattie G, et al
    Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    Breast Cancer Res Treat. 2021;188:739-747.
    >> Share

  5. RUDDY KJ, Zheng Y, Tayob N, Hu J, et al
    Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
    Breast Cancer Res Treat. 2021;189:103-110.
    >> Share

    July 2021
  6. HANNA A, Balko JM
    Breast cancer resistance mechanisms: challenges to immunotherapy.
    Breast Cancer Res Treat. 2021 Jul 28. pii: 10.1007/s10549-021-06337.
    >> Share

  7. JERZAK KJ, Lipton N, Nofech-Mozes S, Boles D, et al
    Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
    Breast Cancer Res Treat. 2021 Jul 27. pii: 10.1007/s10549-021-06327.
    >> Share

  8. EVANS DG, Howell SJ, Gandhi A, van Veen EM, et al
    Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    Breast Cancer Res Treat. 2021 Jul 26. pii: 10.1007/s10549-021-06333.
    >> Share

  9. BALCH SM, Vaz-Luis I, Li T, Tayob N, et al
    A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast ca
    Breast Cancer Res Treat. 2021 Jul 24. pii: 10.1007/s10549-021-06329.
    >> Share

  10. JEON YW, Park HS, Ko Y, Sung YS, et al
    Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Jul 20. pii: 10.1007/s10549-021-06322.
    >> Share

  11. LEI L, Chan HC, Lu TP, Cheng SH, et al
    Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan.
    Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06330.
    >> Share

  12. ALFARSI LH, El Ansari R, Craze ML, Mohammed OJ, et al
    SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06298.
    >> Share

  13. BATENBURG MCT, Maarse W, van der Leij F, Baas IO, et al
    The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients.
    Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06332.
    >> Share

  14. DENT R, Oliveira M, Isakoff SJ, Im SA, et al
    Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jul 15. pii: 10.1007/s10549-021-06143.
    >> Share

  15. BOTTY VAN DEN BRUELE A, Ferraro E, Sevilimedu V, Hogan MP, et al
    Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?
    Breast Cancer Res Treat. 2021 Jul 14. pii: 10.1007/s10549-021-06331.
    >> Share

  16. BEKELE BM, Luijendijk M, Schagen SB, de Ruiter M, et al
    Fatigue and resting-state functional brain networks in breast cancer patients treated with chemotherapy.
    Breast Cancer Res Treat. 2021 Jul 14. pii: 10.1007/s10549-021-06326.
    >> Share

  17. WALBAUM B, Puschel K, Medina L, Merino T, et al
    Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients.
    Breast Cancer Res Treat. 2021 Jul 10. pii: 10.1007/s10549-021-06317.
    >> Share

  18. YAN CH, Coleman C, Nabulsi NA, Chiu BC, et al
    Associations between frailty and cancer-specific mortality among older women with breast cancer.
    Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06323.
    >> Share

  19. PARK J, Tacam MJ, Chauhan G, Cohen EN, et al
    Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.
    Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06316.
    >> Share

  20. COUGHLIN SS, Ayyala DN
    Symptoms associated with comorbid diabetes among breast cancer survivors.
    Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06324.
    >> Share

  21. LIU X, Qiu R, Xu M, Meng M, et al
    KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
    Breast Cancer Res Treat. 2021 Jul 8. pii: 10.1007/s10549-021-06325.
    >> Share

  22. WALLNER LP, Abrahamse P, Gargaro JG, Radhakrishnan A, et al
    Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trial.
    Breast Cancer Res Treat. 2021 Jul 7. pii: 10.1007/s10549-021-06257.
    >> Share

  23. BURKS HE, Matossian MD, Rhodes LV, Phamduy T, et al
    ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism.
    Breast Cancer Res Treat. 2021 Jul 6. pii: 10.1007/s10549-021-06256.
    >> Share

  24. KIM JY, Jeon E, Kwon S, Jung H, et al
    Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
    Breast Cancer Res Treat. 2021 Jul 5. pii: 10.1007/s10549-021-06310.
    >> Share

  25. BENGTSSON Y, Sandsveden M, Borgquist S, Manjer J, et al
    Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study.
    Breast Cancer Res Treat. 2021 Jul 5. pii: 10.1007/s10549-021-06318.
    >> Share

  26. SHARMA U, Medina-Saenz K, Miller PC, Troness B, et al
    Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06299.
    >> Share

  27. JACOBS DHM, Charaghvandi RK, Horeweg N, Maduro JH, et al
    Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06314.
    >> Share

  28. POLLEY MC, Dickler MN, Sinnwell J, Tenner K, et al
    A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06319.
    >> Share

  29. MCGUINNESS JE, Altoe ML, Marone A, Franks LE, et al
    Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06320.
    >> Share

  30. CASTELO M, Brown Z, D'Abbondanza JA, Wasilewski NV, et al
    Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06300.
    >> Share

  31. KEARNEY MR, McGuinness JE, Kalinsky K
    Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06291.
    >> Share

  32. HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
    Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06288.
    >> Share

  33. MATOSSIAN MD, Elliott S, Van Hoang T, Burks HE, et al
    NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06295.
    >> Share

  34. REN M, Orozco A, Shao K, Albanez A, et al
    Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06305.
    >> Share

  35. AL-KAWAZ A, Miligy IM, Toss MS, Mohammed OJ, et al
    The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
    Breast Cancer Res Treat. 2021;188:53-63.
    >> Share

  36. DEMPSEY N, Rosenthal A, Dabas N, Kropotova Y, et al
    Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Breast Cancer Res Treat. 2021;188:21-36.
    >> Share

  37. SUNDARESAN TK, Dubash TD, Zheng Z, Bardia A, et al
    Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Breast Cancer Res Treat. 2021;188:43-52.
    >> Share

  38. BOYER JZ, Phillips GDL, Nitta H, Garsha K, et al
    Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
    Breast Cancer Res Treat. 2021;188:65-75.
    >> Share

  39. AROLE V, Nitta H, Wei L, Shen T, et al
    M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma.
    Breast Cancer Res Treat. 2021;188:37-42.
    >> Share

  40. RAKOVITCH E, Parpia S, Koch A, Grimard L, et al
    DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
    Breast Cancer Res Treat. 2021;188:133-139.
    >> Share

  41. HABIBI M, Prasath V, Dembinski R, Sacks JM, et al
    Comparison of mastectomy and breast reconstruction outcomes using low thermal dissection versus traditional electrocautery: a blinded randomized trial.
    Breast Cancer Res Treat. 2021;188:101-106.
    >> Share

  42. LERTWILAIWITTAYA P, Roothumnong E, Nakthong P, Dungort P, et al
    Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Breast Cancer Res Treat. 2021;188:237-248.
    >> Share

  43. MUNOZ-MONTANO WR, Cabrera-Galeana P, De la Garza-Ramos C, Azim HA Jr, et al
    Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case-control study.
    Breast Cancer Res Treat. 2021;188:489-500.
    >> Share

    June 2021
  44. LOPES CARDOZO JMN, Schmidt MK, van 't Veer LJ, Cardoso F, et al
    Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
    Breast Cancer Res Treat. 2021 Jun 30. pii: 10.1007/s10549-021-06315.
    >> Share

  45. ABUBAKAR M, Guo C, Koka H, Zhu B, et al
    Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    Breast Cancer Res Treat. 2021 Jun 29. pii: 10.1007/s10549-021-06294.
    >> Share

  46. JOHNSON JE, Strassle PD, de Oliveira GC, Agala CB, et al
    Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06303.
    >> Share

  47. FILIPE MD, Siesling S, Vriens MR, van Diest P, et al
    The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06308.
    >> Share

  48. ADEMUYIWA FO, Chen I, Luo J, Rimawi MF, et al
    Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06307.
    >> Share

  49. KEARNEY M, Franks L, Lee S, Tiersten A, et al
    Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
    Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06306.
    >> Share

  50. HAN X, Duan X, Liu Z, Long Y, et al
    ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06301.
    >> Share

  51. BALIJA TM, Braz D, Hyman S, Montgomery LL, et al
    Early reflector localization improves the accuracy of localization and excision of a previously positive axillary lymph node following neoadjuvant chemotherapy in patients with breast cancer.
    Breast Cancer Res Treat. 2021 Jun 23. pii: 10.1007/s10549-021-06281.
    >> Share

  52. COLE KM, Clemons M, Alzahrani M, Larocque G, et al
    Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers.
    Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06186.
    >> Share

  53. KO G, Hota S, Cil TD
    COVID-19 vaccination and breast cancer surgery timing.
    Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06293.
    >> Share

  54. KIM H, Kim YJ, Park D, Park WY, et al
    Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Breast Cancer Res Treat. 2021 Jun 21. pii: 10.1007/s10549-021-06296.
    >> Share

  55. STEBBING J, Baranau YV, Baryash V, Manikhas A, et al
    Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
    Breast Cancer Res Treat. 2021 Jun 20. pii: 10.1007/s10549-021-06240.
    >> Share

  56. REYNA C, Johnston ME, Morris MC, Lee TC, et al
    National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes.
    Breast Cancer Res Treat. 2021 Jun 18. pii: 10.1007/s10549-021-06290.
    >> Share

  57. LIVINGSTON-ROSANOFF D, Trentham-Dietz A, Hampton JM, Newcomb PA, et al
    Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?
    Breast Cancer Res Treat. 2021 Jun 15. pii: 10.1007/s10549-021-06278.
    >> Share

  58. PRIOR L, O'Dwyer R, Farooq AR, Greally M, et al
    Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.
    Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06263.
    >> Share

  59. RUGO HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, et al
    Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06197.
    >> Share

  60. PUMPALOVA YS, Ayeni OA, Chen WC, O'Neil DS, et al
    Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa.
    Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06265.
    >> Share

  61. SKARPING I, Fornvik D, Zackrisson S, Borgquist S, et al
    Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
    Breast Cancer Res Treat. 2021 Jun 12. pii: 10.1007/s10549-021-06283.
    >> Share

  62. ALMODALLAL Y, Le-Rademacher JG, Cook KD, Yadav S, et al
    Observations with alpelisib in older patients (>/= 65 year of age) with breast cancer in a non-clinical trial setting.
    Breast Cancer Res Treat. 2021 Jun 12. pii: 10.1007/s10549-021-06277.
    >> Share

  63. MORIKAWA A, Grkovski M, Patil S, Jhaveri KL, et al
    A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
    Breast Cancer Res Treat. 2021 Jun 10. pii: 10.1007/s10549-021-06209.
    >> Share

  64. DAMIN AP
    Reply to the letter on sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer.
    Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06285.
    >> Share

  65. CAINI S, Fiorito G, Palli D, Bendinelli B, et al
    Pre-diagnostic DNA methylation patterns differ according to mammographic breast density amongst women who subsequently develop breast cancer: a case-only study in the EPIC-Florence cohort.
    Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06273.
    >> Share

  66. NTELIOPOULOS G, Page K, Hills A, Howarth K, et al
    Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
    Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06220.
    >> Share

  67. SZUHANY KL, Malgaroli M, Riley G, Miron CD, et al
    Barriers and engagement in breast cancer survivorship wellness activities.
    Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06279.
    >> Share

  68. BROWN JC, Sarwer DB, Troxel AB, Sturgeon K, et al
    A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity.
    Breast Cancer Res Treat. 2021 Jun 5. pii: 10.1007/s10549-021-06284.
    >> Share

  69. ORTEGA EXPOSITO C, Falo C, Pernas S, Perez Carton S, et al
    The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
    Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06274.
    >> Share

  70. LOPRESTI ML, Bian JJ, Sakr BJ, Strenger RS, et al
    Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
    Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06266.
    >> Share

  71. DIFLORIO-ALEXANDER RM, Song Q, Dwan D, Austin-Strohbehn JA, et al
    Fat-enlarged axillary lymph nodes are associated with node-positive breast cancer in obese patients.
    Breast Cancer Res Treat. 2021 Jun 3. pii: 10.1007/s10549-021-06262.
    >> Share

  72. HAGIWARA Y, Sawaki M, Uemura Y, Kawahara T, et al
    Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
    Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06253.
    >> Share

  73. SAINI G, Gogineni K, Kittles RA, Aneja R, et al
    Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.
    Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06264.
    >> Share

  74. SHAH AN, Carroll KJ, Gerratana L, Lin C, et al
    Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
    Breast Cancer Res Treat. 2021;187:397-405.
    >> Share

  75. MORENO G, Molina M, Wu R, Sullivan JR, et al
    Unveiling the histopathologic spectrum of MRI-guided breast biopsies: an institutional pathological-radiological correlation.
    Breast Cancer Res Treat. 2021;187:673-680.
    >> Share

  76. FEGHHI M, Rezaie J, Mostafanezhad K, Jabbari N, et al
    Bystander effects induced by electron beam-irradiated MCF-7 cells: a potential mechanism of therapy resistance.
    Breast Cancer Res Treat. 2021;187:657-671.
    >> Share

  77. SWARNKAR PK, Mokbel K
    Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Breast Cancer Res Treat. 2021;187:919-920.
    >> Share

  78. GAO Y, Wu N, Wang S, Yang X, et al
    Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.
    Breast Cancer Res Treat. 2021;187:613-624.
    >> Share

  79. AUSTIN-DATTA RJ, Smotherman CR, Yaghjyan L
    Association between rice consumption and risk of cancer incidence in the California Teachers Study.
    Breast Cancer Res Treat. 2021;187:917-918.
    >> Share

  80. TSANG JY, Lai ST, Ni YB, Shao Y, et al
    SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
    Breast Cancer Res Treat. 2021;187:339-347.
    >> Share

  81. PATEL B, Merker L, Sahu A
    Letter to the editor regarding: 'Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire'.
    Breast Cancer Res Treat. 2021;187:601-602.
    >> Share

  82. SALVIAT F, Charles C, Uzan C
    Shall patients' anxiety influence surgical decisions for atypical breast lesions? A substudy of the prospective NOMAT trial.
    Breast Cancer Res Treat. 2021;187:597-599.
    >> Share

  83. STOEN E, Kagihara J, Shagisultanova E, Fisher CM, et al
    Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
    Breast Cancer Res Treat. 2021;187:883-891.
    >> Share

  84. LO GULLO R, Vincenti K, Rossi Saccarelli C, Gibbs P, et al
    Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade.
    Breast Cancer Res Treat. 2021;187:535-545.
    >> Share

    May 2021
  85. BERNHARDT SM, Dasari P, Glynn DJ, Townsend AR, et al
    Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.
    Breast Cancer Res Treat. 2021 May 31. pii: 10.1007/s10549-021-06254.
    >> Share

  86. DIBBLE KE, Baumgartner RN, Boone SD, Baumgartner KB, et al
    Physical activity, ethnicity, and quality of life among breast cancer survivors and population-based controls: the long-term quality of life follow-up study.
    Breast Cancer Res Treat. 2021 May 29. pii: 10.1007/s10549-021-06261.
    >> Share

  87. TRAPANI D, Giugliano F, Uliano J, Zia VAA, et al
    Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
    Breast Cancer Res Treat. 2021 May 27. pii: 10.1007/s10549-021-06259.
    >> Share

  88. HARATI R, Mabondzo A, Tlili A, Khoder G, et al
    Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2021 May 26. pii: 10.1007/s10549-021-06255.
    >> Share

  89. MILLER MM, Meneveau MO, Rochman CM, Schroen AT, et al
    Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors.
    Breast Cancer Res Treat. 2021 May 25. pii: 10.1007/s10549-021-06252.
    >> Share

  90. JOOSEN MEM, Schop SJ, Reinhoudt LL, van Kuijk SMJ, et al
    The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study.
    Breast Cancer Res Treat. 2021 May 24. pii: 10.1007/s10549-021-06199.
    >> Share

  91. DELRIEU L, Martin A, Touillaud M, Perol O, et al
    Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial.
    Breast Cancer Res Treat. 2021 May 19. pii: 10.1007/s10549-021-06238.
    >> Share

  92. ZHOU Y, Xu Y, Wang C, Gong Y, et al
    Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2021 May 18. pii: 10.1007/s10549-021-06247.
    >> Share

  93. EUSTACE AJ, Madden SF, Fay J, Collins DM, et al
    The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2021 May 13. pii: 10.1007/s10549-021-06244.
    >> Share

  94. ARJMANDI F, Mootz A, Farr D, Reddy S, et al
    New horizons in imaging and surgical assessment of breast cancer lymph node metastasis.
    Breast Cancer Res Treat. 2021 May 12. pii: 10.1007/s10549-021-06248.
    >> Share

  95. ZHU Q, Ademuyiwa FO, Young C, Appleton C, et al
    Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography.
    Breast Cancer Res Treat. 2021 May 10. pii: 10.1007/s10549-021-06239.
    >> Share

  96. CHUN JW, Kim J, Chung IIY, Ko BS, et al
    Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 May 8. pii: 10.1007/s10549-021-06249.
    >> Share

  97. WATANABE J, Mitsuya K, Nakamoto S, Harada H, et al
    Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period.
    Breast Cancer Res Treat. 2021 May 8. pii: 10.1007/s10549-021-06246.
    >> Share

  98. KUMAR S, Bal A, Das A, Loriya I, et al
    Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 May 5. pii: 10.1007/s10549-021-06242.
    >> Share

  99. SWARNKAR PK, Mokbel K
    Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Breast Cancer Res Treat. 2021 May 5. pii: 10.1007/s10549-021-06222.
    >> Share

  100. TAN EH, Wong ALA, Tan CC, Wong P, et al
    Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
    Breast Cancer Res Treat. 2021 May 4. pii: 10.1007/s10549-021-06204.
    >> Share

  101. GROEN EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, et al
    Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2021 May 4. pii: 10.1007/s10549-021-06235.
    >> Share

  102. SILVA SN, Gomes BC, Andre S, Felix A, et al
    Male and female breast cancer: the two faces of the same genetic susceptibility coin.
    Breast Cancer Res Treat. 2021 May 3. pii: 10.1007/s10549-021-06159.
    >> Share

  103. SIEGEL EL, Whiting J, Kim Y, Sun W, et al
    Effect of surgical complications on outcomes in breast cancer patients treated with mastectomy and immediate reconstruction.
    Breast Cancer Res Treat. 2021 May 3. pii: 10.1007/s10549-021-06241.
    >> Share

  104. MCLEMORE LE, Albarracin CT, Gruschkus SK, Bassett RL Jr, et al
    HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
    Breast Cancer Res Treat. 2021;187:95-104.
    >> Share

  105. HUANG S, Houssami N, Brennan M, Nickel B, et al
    The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review.
    Breast Cancer Res Treat. 2021;187:11-30.
    >> Share

  106. DEL VALLE DD, Pardo JA, Maselli AM, Valero MG, et al
    Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
    Breast Cancer Res Treat. 2021;187:1-9.
    >> Share

  107. VAN DEN BRUELE AB, Chen I, Sevilimedu V, Le T, et al
    Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy.
    Breast Cancer Res Treat. 2021;187:105-112.
    >> Share

  108. ALANKO J, Tanner M, Vanninen R, Auvinen A, et al
    Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.
    Breast Cancer Res Treat. 2021;187:267-274.
    >> Share

  109. THEBERGE I, Vandal N, Perron L, Guertin MH, et al
    Association between radiologists' and facilities' characteristics and mammography screening detection of ductal carcinoma in situ.
    Breast Cancer Res Treat. 2021;187:255-266.
    >> Share

  110. BYNG D, Retel VP, Schaapveld M, Wesseling J, et al
    Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
    Breast Cancer Res Treat. 2021;187:187-196.
    >> Share

  111. LUITEN JD, Luiten EJT, van der Sangen MJC, Vreuls W, et al
    Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.
    Breast Cancer Res Treat. 2021;187:245-254.
    >> Share

    April 2021
  112. VIDULA N, Yau C, Rugo HS
    Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
    Breast Cancer Res Treat. 2021 Apr 28. pii: 10.1007/s10549-021-06234.
    >> Share

  113. MOY B, Oliveira M, Saura C, Gradishar W, et al
    Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >/= 2 prior HER2-directed regimens.
    Breast Cancer Res Treat. 2021 Apr 28. pii: 10.1007/s10549-021-06217.
    >> Share

  114. KAZMI S, Chatterjee D, Raju D, Hauser R, et al
    Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
    Breast Cancer Res Treat. 2021 Apr 27. pii: 10.1007/s10549-021-06223.
    >> Share

  115. LEONARDI MC, Scognamiglio IR, Maisonneuve P, Dicuonzo S, et al
    Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated.
    Breast Cancer Res Treat. 2021 Apr 27. pii: 10.1007/s10549-021-06227.
    >> Share

  116. WANG Z, Liu J, Ma F, Wang J, et al
    Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Breast Cancer Res Treat. 2021 Apr 25. pii: 10.1007/s10549-021-06216.
    >> Share

  117. GRUSLOVA A, McClellan B, Balinda HU, Viswanadhapalli S, et al
    FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
    Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06231.
    >> Share

  118. BHARDWAJ A, Embury MD, Rojo RD, Albarracin C, et al
    Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer.
    Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06229.
    >> Share

  119. LEONE JP, Vallejo CT, Hassett MJ, Leone J, et al
    Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
    Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06233.
    >> Share

  120. KOH M, Jung J, Kim SS, Do Ahn S, et al
    Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06228.
    >> Share

  121. STROJNIK K, Krajc M, Dragos VS, Stegel V, et al
    Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
    Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06224.
    >> Share

  122. VERON L, Wehrer D, Annerose-Zephir G, Suciu V, et al
    Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up.
    Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06226.
    >> Share

  123. LEPROUX C, Seegers V, Patsouris A, Sauterey B, et al
    Success and risks of pregnancy after breast cancer.
    Breast Cancer Res Treat. 2021 Apr 21. pii: 10.1007/s10549-021-06232.
    >> Share

  124. CHEN M, Zhao Y, Yang X, Zhao Y, et al
    NSDHL promotes triple-negative breast cancer metastasis through the TGFbeta signaling pathway and cholesterol biosynthesis.
    Breast Cancer Res Treat. 2021 Apr 16. pii: 10.1007/s10549-021-06213.
    >> Share

  125. HUANG CS, Yang Y, Kwong A, Chen SC, et al
    Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
    Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06166.
    >> Share

  126. KOCA E, Niravath PA, Ensor J, Patel TA, et al
    ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06214.
    >> Share

  127. HEQUET D, Harrissart G, Krief D, Maumy L, et al
    Prosigna test in breast cancer: real-life experience.
    Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06191.
    >> Share

  128. SALEH B, Elhawary MA, Mohamed ME, Ali IN, et al
    Gail model utilization in predicting breast cancer risk in Egyptian women: a cross-sectional study.
    Breast Cancer Res Treat. 2021 Apr 14. pii: 10.1007/s10549-021-06200.
    >> Share

  129. HADDAD TC, He J, O'Sullivan CC, Chen B, et al
    Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
    Breast Cancer Res Treat. 2021 Apr 14. pii: 10.1007/s10549-021-06221.
    >> Share

  130. PAI T, Cornell L, Seneviratne D, Niazi S, et al
    Pre-diagnosis major life stressors and breast cancer outcomes.
    Breast Cancer Res Treat. 2021 Apr 12. pii: 10.1007/s10549-021-06218.
    >> Share

  131. HOPSON MB, Lee S, Accordino M, Trivedi M, et al
    Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06210.
    >> Share

  132. KEELAN S, Heeney A, Downey E, Hegarty A, et al
    Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06194.
    >> Share

  133. KRISTENSEN KB, Thomsen IMN, Berg T, Kodahl AR, et al
    Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06215.
    >> Share

  134. MCSORLEY LM, Tharmabala M, Al Rahbi F, McSorley K, et al
    Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
    Breast Cancer Res Treat. 2021 Apr 9. pii: 10.1007/s10549-021-06211.
    >> Share

  135. JOHNSON AE, Coopey SB, Spring LM, Horick NK, et al
    Management and outcomes of men diagnosed with primary breast cancer.
    Breast Cancer Res Treat. 2021 Apr 8. pii: 10.1007/s10549-021-06174.
    >> Share

  136. TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
    Correction to: Mammography use and breast cancer incidence among older U.S. women.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06212.
    >> Share

  137. BATTISTI NML, Andres MS, Lee KA, Ramalingam S, et al
    Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06192.
    >> Share

  138. CHETRIT A, Ben-Avraham S, Mandelzweig L, Amitai T, et al
    Breast cancer survivors: physical and mental quality of life 10 years following diagnosis, a case-control study.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06156.
    >> Share

  139. SUTTON AL, Felix AS, Bandyopadhyay D, Retnam R, et al
    Cardioprotective medication use in Black and white breast cancer survivors.
    Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06202.
    >> Share

  140. CHALASANI P, Farr K, Wu V, Jenkins I, et al
    Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06175.
    >> Share

  141. PAWLOSKI KR, Tadros AB, Sevilimedu V, Newman A, et al
    Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Breast Cancer Res Treat. 2021;186:617-624.
    >> Share

  142. KOJIMAHARA T, Kageyama T
    Octopus anastomosis: selection of anastomotic configuration in lymphaticovenular anastomosis according to vessels' conditions.
    Breast Cancer Res Treat. 2021;186:887-888.
    >> Share

  143. LANCETA L, Lypova N, O'Neill C, Li X, et al
    Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
    Breast Cancer Res Treat. 2021;186:677-686.
    >> Share

  144. JIAGGE EM, Ulintz PJ, Wong S, McDermott SP, et al
    Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry.
    Breast Cancer Res Treat. 2021;186:391-401.
    >> Share

  145. PARKES A, Wang WL, Patel S, Leung CH, et al
    Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
    Breast Cancer Res Treat. 2021;186:871-882.
    >> Share

  146. GRILL S, Yahiaoui-Doktor M, Basrai M, Struck J, et al
    Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
    Breast Cancer Res Treat. 2021;186:741-752.
    >> Share

  147. YANG L, Roy M, Lin H, Shen Y, et al
    Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.
    Breast Cancer Res Treat. 2021;186:403-415.
    >> Share

  148. ZHI WI, Baser RE, Kwon A, Chen C, et al
    Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
    Breast Cancer Res Treat. 2021;186:761-768.
    >> Share

  149. ALDOSARY G, Caudrelier JM, Arnaout A, Chang L, et al
    Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?
    Breast Cancer Res Treat. 2021;186:343-352.
    >> Share

  150. FILIPE MD, Patuleia SIS, Vriens MR, van Diest PJ, et al
    Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge.
    Breast Cancer Res Treat. 2021;186:285-293.
    >> Share

  151. GUI G, Panopoulou E, Tang S, Twelves D, et al
    The INTEND 1 randomized controlled trial of duct endoscopy as an indicator of margin excision in breast conservation surgery.
    Breast Cancer Res Treat. 2021;186:723-730.
    >> Share

  152. HUANG CS, Lu TP, Liu CY, Huang CJ, et al
    Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature.
    Breast Cancer Res Treat. 2021;186:475-485.
    >> Share

  153. HA SM, Chang JM, Kim SY, Lee SH, et al
    Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI.
    Breast Cancer Res Treat. 2021;186:463-473.
    >> Share

  154. KELLY BN, Kantor O, Tang R, Coopey SB, et al
    Similar rates of residual disease in patients with DCIS within 2 mm of lumpectomy margin regardless of the presence of invasive carcinoma.
    Breast Cancer Res Treat. 2021;186:807-814.
    >> Share

  155. HALASZ SR, O'Keefe T, Wallace AM, Blair SL, et al
    Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
    Breast Cancer Res Treat. 2021;186:551-559.
    >> Share

    March 2021
  156. HELBRICH H, Braun M, Hanusch C, Mueller G, et al
    Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer.
    Breast Cancer Res Treat. 2021 Mar 31. pii: 10.1007/s10549-021-06195.
    >> Share

  157. WANG YQ, Huang G, Chen J, Cao H, et al
    LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06190.
    >> Share

  158. NISHIKAWA S, Uemoto Y, Kim TS, Hisada T, et al
    Low RAI2 expression is a marker of poor prognosis in breast cancer.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06176.
    >> Share

  159. AN KY, Arthuso FZ, Kang DW, Morielli AR, et al
    Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06205.
    >> Share

  160. REINHORN D, Kuchuk I, Shochat T, Nisenbaum B, et al
    Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
    Breast Cancer Res Treat. 2021 Mar 27. pii: 10.1007/s10549-021-06198.
    >> Share

  161. LEONE J, Freedman RA, Lin NU, Tolaney SM, et al
    Tumor subtypes and survival in male breast cancer.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06182.
    >> Share

  162. AHN SG, Kim SK, Shepherd JH, Cha YJ, et al
    Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06193.
    >> Share

  163. OPPONG BA, Obeng-Gyasi S, Relation T, Adams-Campbell L, et al
    Call to action: breast cancer screening recommendations for Black women.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06207.
    >> Share

  164. CHEN I, Botty Van den Bruele AM, Gillespie EF, Mueller BA, et al
    Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06206.
    >> Share

  165. HO PJ, Dorajoo R, Ivankovic I, Ong SS, et al
    DNA methylation and breast cancer-associated variants.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06185.
    >> Share

  166. MASUDA N, Bando H, Yamanaka T, Kadoya T, et al
    Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    Breast Cancer Res Treat. 2021 Mar 25. pii: 10.1007/s10549-021-06184.
    >> Share

  167. WANG C, Tong F, Cao Y, Liu P, et al
    Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer.
    Breast Cancer Res Treat. 2021 Mar 24. pii: 10.1007/s10549-021-06196.
    >> Share

  168. MCGEE S, Alzahrani M, Vandermeer L, Cole K, et al
    Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
    Breast Cancer Res Treat. 2021 Mar 23. pii: 10.1007/s10549-021-06147.
    >> Share

  169. THOMAS S, Kabir M, Butcher BE, Chou S, et al
    Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer.
    Breast Cancer Res Treat. 2021 Mar 22. pii: 10.1007/s10549-021-06188.
    >> Share

  170. BUCKLEY E, Elder E, McGill S, Kargar ZS, et al
    Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia.
    Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06170.
    >> Share

  171. KUEMMEL S, Tondini CA, Abraham J, Nowecki Z, et al
    Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
    Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06145.
    >> Share

  172. IBRAGIMOVA KIE, Geurts SME, Croes S, Erdkamp F, et al
    Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
    Breast Cancer Res Treat. 2021 Mar 20. pii: 10.1007/s10549-021-06178.
    >> Share

  173. GHARZAI LA, Szczygiel LA, Shumway DA, Bandos H, et al
    A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06172.
    >> Share

  174. WU ZY, Han HH, Kim HJ, Lee JW, et al
    A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06114.
    >> Share

  175. SHEEAN P, Matthews L, Visotcky A, Banerjee A, et al
    Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06163.
    >> Share

  176. LLOYD KE, Hall LH, Ziegler L, Smith SG, et al
    Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06183.
    >> Share

  177. TOKUDA Y, Yanagawa M, Fujita Y, Honma K, et al
    Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
    Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06179.
    >> Share

  178. IM YH, Karabulut B, Lee KS, Park BW, et al
    Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
    Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06173.
    >> Share

  179. SURETTE A, Yoo BH, Younis T, Matheson K, et al
    Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
    Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06164.
    >> Share

  180. HETTERICH M, Gerken M, Ortmann O, Inwald EC, et al
    Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
    Breast Cancer Res Treat. 2021 Mar 15. pii: 10.1007/s10549-021-06162.
    >> Share

  181. WALSTRA CJEF, Schipper RJ, van Riet YE, van der Toorn PG, et al
    Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands.
    Breast Cancer Res Treat. 2021 Mar 13. pii: 10.1007/s10549-021-06154.
    >> Share

  182. FALTINOVA M, Vehmanen L, Lyytinen H, Haanpaa M, et al
    Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
    Breast Cancer Res Treat. 2021 Mar 12. pii: 10.1007/s10549-021-06168.
    >> Share

  183. LI XM, Chen HL
    RE: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early stage breast cancer patients.
    Breast Cancer Res Treat. 2021 Mar 11. pii: 10.1007/s10549-021-06146.
    >> Share

  184. FEI F, Siegal GP, Wei S
    Characterization of estrogen receptor-low-positive breast cancer.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06148.
    >> Share

  185. MOOSSDORFF M, Vane MLG, van Nijnatten TJA, van Maaren MC, et al
    Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-020-06040.
    >> Share

  186. DANKWA-MULLAN I, George J, Roebuck MC, Tkacz J, et al
    Variations in breast cancer surgical treatment and timing: determinants and disparities.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06155.
    >> Share

  187. PRADA D, Baccarelli AA, Terry MB, Valdez L, et al
    Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer.
    Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06167.
    >> Share

  188. CHAWLA S, Hill A, Fearfield L, Johnston S, et al
    Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
    Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06169.
    >> Share

  189. LUO J, Kroenke CH, Hendryx M, Shadyab AH, et al
    Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women.
    Breast Cancer Res Treat. 2021 Mar 7. pii: 10.1007/s10549-021-06158.
    >> Share

  190. FALCONE M, Liu L, Farias A, Zhang J, et al
    Evidence for racial/ethnic disparities in emergency department visits following breast cancer surgery among women in California: a population-based study.
    Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06119.
    >> Share

  191. NGUYEN T, Irwin ML, Dewan AT, Cartmel B, et al
    Examining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention.
    Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06151.
    >> Share

  192. TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
    Mammography use and breast cancer incidence among older U.S. women.
    Breast Cancer Res Treat. 2021 Mar 5. pii: 10.1007/s10549-021-06160.
    >> Share

  193. ZDRAVKOVIC D, Petricevic S, Toskovic B
    Influence of different response after neoadjuvant chemotherapy on time of surgery in breast cancer patients.
    Breast Cancer Res Treat. 2021 Mar 4. pii: 10.1007/s10549-021-06161.
    >> Share

  194. STRELL C, Stenmark Tullberg A, Jetne Edelmann R, Akslen LA, et al
    Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial.
    Breast Cancer Res Treat. 2021 Mar 4. pii: 10.1007/s10549-021-06136.
    >> Share

  195. SMITH SG, Sestak I, Morris MA, Harvie M, et al
    The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
    Breast Cancer Res Treat. 2021 Mar 3. pii: 10.1007/s10549-021-06141.
    >> Share

  196. PARK KU, Gregory M, Bazan J, Lustberg M, et al
    Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic.
    Breast Cancer Res Treat. 2021 Mar 2. pii: 10.1007/s10549-021-06153.
    >> Share

  197. O'SHAUGHNESSY J, Robert N, Annavarapu S, Zhou J, et al
    Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
    Breast Cancer Res Treat. 2021 Mar 1. pii: 10.1007/s10549-021-06137.
    >> Share

  198. IACUZZO C, Giudici F, Scomersi S, Ceccherini R, et al
    Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice.
    Breast Cancer Res Treat. 2021 Mar 1. pii: 10.1007/s10549-021-06144.
    >> Share

    February 2021
  199. KAUFMAN PA, Hurvitz SA, O'Shaughnessy J, Mason G, et al
    Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
    Breast Cancer Res Treat. 2021 Feb 28. pii: 10.1007/s10549-021-06103.
    >> Share

  200. SUELMANN BBM, van Dooijeweert C, van der Wall E, Linn S, et al
    Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile.
    Breast Cancer Res Treat. 2021 Feb 26. pii: 10.1007/s10549-021-06130.
    >> Share

  201. TARANTINO P, Curigliano G
    Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06150.
    >> Share

  202. LIU J, Li Y, Li Q, Liang D, et al
    Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06128.
    >> Share

  203. WANG YF, Wang XJ, Lu Z, Liu SR, et al
    Overexpression of Stat3 increases circulating cfDNA in breast cancer.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06142.
    >> Share

  204. WARE AW, Harris JJ, Slatter TL, Cunliffe HE, et al
    The epithelial sodium channel has a role in breast cancer cell proliferation.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06133.
    >> Share

  205. BRUNELLE CL, Barrio AV, Taghian AG
    Letter to editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements".
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06139.
    >> Share

  206. CHANDRIKA M, Chua PJ, Muniasamy U, Huang RYJ, et al
    Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
    Breast Cancer Res Treat. 2021 Feb 24. pii: 10.1007/s10549-021-06123.
    >> Share

  207. PRUITT SL, Zhu H, Heitjan DF, Rahimi A, et al
    Survival of women diagnosed with breast cancer and who have survived a previous cancer.
    Breast Cancer Res Treat. 2021 Feb 23. pii: 10.1007/s10549-021-06122.
    >> Share

  208. VALLA M, Opdahl S, Ytterhus B, Bofin AM, et al
    DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06138.
    >> Share

  209. TANG M, Schaffer AL, Kiely BE, Daniels B, et al
    Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06135.
    >> Share

  210. GUHA R, Yue B, Dong J, Banerjee A, et al
    Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06120.
    >> Share

  211. DUARTE C, Salazar A, Strasser-Weippl K, de Vries E, et al
    Breast cancer in Colombia: a growing challenge for the healthcare system.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-020-06091.
    >> Share

  212. MAN V, Kwong A
    Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06118.
    >> Share

  213. LANAHAN CR, Kelly BN, Gadd MA, Specht MC, et al
    Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06106.
    >> Share

  214. TESCH ME, Chia SK, Simmons CE, LeVasseur N, et al
    Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
    Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06110.
    >> Share

  215. JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
    Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.
    Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06113.
    >> Share

  216. RITTER M, Ling BM, Oberhauser I, Montagna G, et al
    The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery.
    Breast Cancer Res Treat. 2021 Feb 19. pii: 10.1007/s10549-021-06126.
    >> Share

  217. CHEN QX, Yang YZ, Liang ZZ, Chen JL, et al
    Time-varying effects of FOXA1 on breast cancer prognosis.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06125.
    >> Share

  218. KIM J, Hong S, Lee JJ, Won YJ, et al
    Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06107.
    >> Share

  219. ALBINSAAD LS, Kim J, Chung IY, Ko BS, et al
    Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06134.
    >> Share

  220. KIM KH, Choi S, Kim K, Chang J, et al
    Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06140.
    >> Share

  221. CAO S, Zhu Z, Zhou J, Li W, et al
    Associations of one-carbon metabolism-related gene polymorphisms with breast cancer risk are modulated by diet, being higher when adherence to the Mediterranean dietary pattern is low.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06108.
    >> Share

  222. GEBREMARIAM A, Assefa M, Addissie A, Worku A, et al
    Delayed initiation of adjuvant chemotherapy among women with breast cancer in Addis Ababa, Ethiopia.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06131.
    >> Share

  223. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, Gal R, et al
    (Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06112.
    >> Share

  224. WANG Y, Singh K, Dizon D, Graves T, et al
    Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Breast Cancer Res Treat. 2021 Feb 17. pii: 10.1007/s10549-021-06124.
    >> Share

  225. JALLOUK AP, Paravastu S, Weilbaecher K, Aft RL, et al
    Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06100.
    >> Share

  226. WARDLEY A, Cortes J, Provencher L, Miller K, et al
    The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06109.
    >> Share

  227. LEONE JP, Leone BA, Tayob N, Hassett MJ, et al
    Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06121.
    >> Share

  228. NGUY S, Wu SP, Oh C, Gerber NK, et al
    Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
    Breast Cancer Res Treat. 2021 Feb 15. pii: 10.1007/s10549-021-06115.
    >> Share

  229. LIZARRAGA IM, Kahl AR, Jacoby E, Charlton ME, et al
    Impact of age, rurality and distance in predicting contralateral prophylactic mastectomy for breast cancer in a Midwestern state: a population-based study.
    Breast Cancer Res Treat. 2021 Feb 13. pii: 10.1007/s10549-021-06105.
    >> Share

  230. PEATE M, Saunders C, Cohen P, Hickey M, et al
    Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors.
    Breast Cancer Res Treat. 2021 Feb 11. pii: 10.1007/s10549-021-06117.
    >> Share

  231. LIU M, Xie F, Liu M, Zhang Y, et al
    Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021 Feb 9. pii: 10.1007/s10549-021-06104.
    >> Share

  232. COLETTA AM, Agha NH, Baker FL, Niemiro GM, et al
    The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
    Breast Cancer Res Treat. 2021 Feb 8. pii: 10.1007/s10549-021-06111.
    >> Share

  233. DA SILVA LR, de Andrade CA, Brenelli F, Ramalho S, et al
    Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2021 Feb 4. pii: 10.1007/s10549-020-06076.
    >> Share

  234. RAFN BS, Christensen J, Bloomquist K
    Letter to the editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancerrelated lymphedema: a metaanalysis comparing bioimpedance spectroscopy versus circumferential measurements".
    Breast Cancer Res Treat. 2021;186:269-270.
    >> Share

  235. YANG C, Arnold AG, Catchings A, Rai V, et al
    The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
    Breast Cancer Res Treat. 2021;185:869-877.
    >> Share

  236. SHANI H, Bernstein-Molho R, Laitman Y, Netzer I, et al
    Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
    Breast Cancer Res Treat. 2021;186:259-263.
    >> Share

  237. SCHUMACHER K, Inciardi M, O'Neil M, Wagner JL, et al
    Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?
    Breast Cancer Res Treat. 2021;185:567-572.
    >> Share

  238. WU JM, Galibois AA, Seebocus N, Apu A, et al
    HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study.
    Breast Cancer Res Treat. 2021;186:99-105.
    >> Share

  239. ZHANG Z, Chen X, Zhang J, Dai X, et al
    Cancer stem cell transcriptome landscape reveals biomarkers driving breast carcinoma heterogeneity.
    Breast Cancer Res Treat. 2021;186:89-98.
    >> Share

  240. OHNO S, Saji S, Masuda N, Tsuda H, et al
    Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N.SAS-BC 01 trial and CUBC trial).
    Breast Cancer Res Treat. 2021;186:135-147.
    >> Share

  241. KOPANS DB
    The wisdom trial is based on faulty reasoning and has major design and execution problems.
    Breast Cancer Res Treat. 2021;185:549-556.
    >> Share

  242. PARKS RM, Albanghali MA, Syed BM, Green AR, et al
    Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
    Breast Cancer Res Treat. 2021;185:647-655.
    >> Share

  243. MESSORI A, Bartoli L, Ferracane E
    Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis.
    Breast Cancer Res Treat. 2021;185:887.
    >> Share

  244. LACOUTURE ME, Dion H, Ravipaty S, Jimenez JJ, et al
    A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.
    Breast Cancer Res Treat. 2021;186:107-114.
    >> Share

  245. NARAYAN AK, Mercaldo SF, Gupta YP, Warner ET, et al
    Potential of using mammography screening appointments to identify high-risk women: cross sectional survey results from the national health interview survey.
    Breast Cancer Res Treat. 2021;186:229-235.
    >> Share

  246. RABAGLIO M, Sun Z, Maibach R, Giobbie-Hurder A, et al
    Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
    Breast Cancer Res Treat. 2021;185:697-707.
    >> Share

  247. RASCHI E, Fusaroli M, Ardizzoni A, Poluzzi E, et al
    Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Breast Cancer Res Treat. 2021;186:219-227.
    >> Share

  248. TARANTINO P, Prat A, Curigliano G
    New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
    Breast Cancer Res Treat. 2021;185:879-881.
    >> Share

  249. GOMES R, Spinola PDS, Brant AC, Matta BP, et al
    Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Breast Cancer Res Treat. 2021;185:851-861.
    >> Share

  250. ALIPOUR S
    Re: Naoum et al., Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
    Breast Cancer Res Treat. 2021;185:885-886.
    >> Share

  251. RAPHAEL DANIELA DB, Russell NS, van Werkhoven E, Immink JM, et al
    Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.
    Breast Cancer Res Treat. 2021;185:685-695.
    >> Share

  252. LI X, Ma Z, Styblo TM, Arciero CA, et al
    Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.
    Breast Cancer Res Treat. 2021;185:573-581.
    >> Share

  253. LLANOS AAM, Yao S, Singh A, Aremu JB, et al
    Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features.
    Breast Cancer Res Treat. 2021;185:785-798.
    >> Share

    January 2021
  254. YAO KA, Attai D, Bleicher R, Kuchta K, et al
    Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study).
    Breast Cancer Res Treat. 2021 Jan 31. pii: 10.1007/s10549-021-06101.
    >> Share

  255. SHARMA R
    Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018.
    Breast Cancer Res Treat. 2021 Jan 30. pii: 10.1007/s10549-020-06083.
    >> Share

  256. VAN DOOIJEWEERT C, Baas IO, Deckers IAG, Siesling S, et al
    The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 30. pii: 10.1007/s10549-021-06098.
    >> Share

  257. SUKUMAR J, Kassem M, Agnese D, Pilarski R, et al
    Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    Breast Cancer Res Treat. 2021 Jan 28. pii: 10.1007/s10549-021-06095.
    >> Share

  258. ZHAO H, Song R, Ye Y, Chow WH, et al
    Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 28. pii: 10.1007/s10549-021-06102.
    >> Share

  259. KELLY KN, Hernandez A, Yadegarynia S, Ryon E, et al
    Overcoming disparities: Multidisciplinary breast cancer care at a public safety net hospital.
    Breast Cancer Res Treat. 2021 Jan 25. pii: 10.1007/s10549-020-06044.
    >> Share

  260. WEBBER C, Whitehead M, Eisen A, Holloway CMB, et al
    Factors associated with waiting time to breast cancer diagnosis among symptomatic breast cancer patients: a population-based study from Ontario, Canada.
    Breast Cancer Res Treat. 2021 Jan 24. pii: 10.1007/s10549-020-06051.
    >> Share

  261. SUEOKA S, Sasada S, Masumoto N, Emi A, et al
    Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer.
    Breast Cancer Res Treat. 2021 Jan 23. pii: 10.1007/s10549-020-06088.
    >> Share

  262. DODINGTON DW, Lagree A, Tabbarah S, Mohebpour M, et al
    Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 23. pii: 10.1007/s10549-020-06093.
    >> Share

  263. JAFARI L, Akhter N
    Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
    Breast Cancer Res Treat. 2021 Jan 22. pii: 10.1007/s10549-021-06096.
    >> Share

  264. AL-MASRI M, Aljalabneh B, Al-Najjar H, Al-Shamaileh T, et al
    Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes.
    Breast Cancer Res Treat. 2021 Jan 21. pii: 10.1007/s10549-020-06090.
    >> Share

  265. IWASE T, Wang X, Shrimanker TV, Kolonin MG, et al
    Body composition and breast cancer risk and treatment: mechanisms and impact.
    Breast Cancer Res Treat. 2021 Jan 21. pii: 10.1007/s10549-020-06092.
    >> Share

  266. MONDACA JM, Guijarro ACC, Flamini MI, Sanchez AM, et al
    Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.
    Breast Cancer Res Treat. 2021 Jan 20. pii: 10.1007/s10549-020-06089.
    >> Share

  267. SHECKTER CC, Aliu O, Bailey C, Liu J, et al
    Exploring provider- and practice-level drivers of cost-consciousness in breast cancer reconstruction-secondary analysis of a survey of the American Society of Plastic Surgeons.
    Breast Cancer Res Treat. 2021 Jan 19. pii: 10.1007/s10549-020-06085.
    >> Share

  268. KARADSHEH MJ, Tyrell R, Deng M, Egleston BL, et al
    Early postoperative outcomes in implant, pedicled, and free flap reconstruction for breast cancer: an analysis of 23,834 patients from the ACS-NSQIP datasets.
    Breast Cancer Res Treat. 2021 Jan 19. pii: 10.1007/s10549-020-06073.
    >> Share

  269. NAKASHOJI A, Hayashida T, Yamaguchi S, Kawai Y, et al
    Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and development.
    Breast Cancer Res Treat. 2021 Jan 18. pii: 10.1007/s10549-020-06087.
    >> Share

  270. COOLBRANDT A, T'Jonck A, Blauwens K, Dejaeger E, et al
    Scalp cooling in breast cancer patients treated with docetaxel-cyclophosphamide: patient- and nurse-reported results.
    Breast Cancer Res Treat. 2021 Jan 16. pii: 10.1007/s10549-020-06063.
    >> Share

  271. OBA T, Ono M, Matoba H, Uehara T, et al
    HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 16. pii: 10.1007/s10549-020-06033.
    >> Share

  272. APTECAR L, Fiteni F, Jarlier M, Delaine S, et al
    Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients.
    Breast Cancer Res Treat. 2021 Jan 15. pii: 10.1007/s10549-020-06062.
    >> Share

  273. QI P, Yang Y, Bai QM, Xue T, et al
    Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 13. pii: 10.1007/s10549-020-06075.
    >> Share

  274. RICHARDSON D, Zhan L, Mahtani R, McRoy L, et al
    A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application.
    Breast Cancer Res Treat. 2021 Jan 11. pii: 10.1007/s10549-020-06082.
    >> Share

  275. STJEPANOVIC N, Lubinski J, Moller P, Randall Armel S, et al
    Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2021 Jan 10. pii: 10.1007/s10549-020-06072.
    >> Share

  276. ALEIXO GFP, Yu H, Chen YT, Nyrop KA, et al
    Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Jan 10. pii: 10.1007/s10549-020-06061.
    >> Share

  277. WEI M, Wang X, Zimmerman DN, Burt LM, et al
    Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06071.
    >> Share

  278. ZHANG J, Liu Y, Pu S, He J, et al
    Spindle and kinetochoreassociated complex subunit 3 accelerates breast cancer cell proliferation and invasion through the regulation of Akt/Wnt/beta-catenin signaling.
    Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06078.
    >> Share

  279. SOARES ICS, Bello MA, Bergmann A, Thuler LCS, et al
    Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06077.
    >> Share

  280. KUMAR U, Ardasheva A, Mahmud Z, Coombes RC, et al
    FOXA1 is a determinant of drug resistance in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06068.
    >> Share

  281. DI MICCO R, Classe JM, Reimer T
    Letter to the Editor regarding the publication titled "Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?"
    Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06064.
    >> Share

  282. VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
    Correction to: Behavior of metastatic breast cancer according to subtype.
    Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06006.
    >> Share

  283. KHOURY K, Lynce F, Barac A, Geng X, et al
    Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
    Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06053.
    >> Share

  284. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan.
    Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06069.
    >> Share

  285. MACKEY JR, Lai J, Chauhan U, Beauchamp E, et al
    N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06037.
    >> Share

  286. GAUDET MM, Deubler E, Diver WR, Puvanesarajah S, et al
    Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06025.
    >> Share

  287. BOUWER NI, Steenbruggen TG, van Rosmalen J, Rier HN, et al
    Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06039.
    >> Share

  288. KIM JS, Kim K, Jung W, Shin KH, et al
    New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06043.
    >> Share

  289. KLEINSTERN G, Scott CG, Tamimi RM, Jensen MR, et al
    Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06049.
    >> Share

  290. WILLIAMS AM, Khan CP, Heckler CE, Barton DL, et al
    Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06067.
    >> Share

  291. RAJAGOPAL T, Seshachalam A, Rathnam KK, Jothi A, et al
    Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06028.
    >> Share

  292. SUTHERLAND A, Wagner JL, Korentager S, Butterworth J, et al
    Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06059.
    >> Share

  293. ZEIDMAN M, Schmidt H, Alberty-Oller JJ, Pisapati KV, et al
    Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06041.
    >> Share

  294. MORAVEK MB, Confino R, Lawson AK, Smith KN, et al
    Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06031.
    >> Share

  295. LI Z, Wang Y, Liu C, Wang Z, et al
    Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06024.
    >> Share

  296. GOETZ MP, Okera M, Wildiers H, Campone M, et al
    Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06029.
    >> Share

  297. STENEHJEM DD, Telford C, Unni SK, Bauer H, et al
    BRCA testing and outcomes in women with breast cancer.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06038.
    >> Share

  298. POLLEY MC, Leon-Ferre RA, Leung S, Cheng A, et al
    A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06030.
    >> Share

  299. JONES S, Hogan B, Patel K, Ooi S, et al
    Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06046.
    >> Share

  300. KENNARD K, Buckley ME, Sizer LM, Larson S, et al
    Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06034.
    >> Share

  301. LUANGWATTANANUN P, Junking M, Sujjitjoon J, Wutti-In Y, et al
    Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06032.
    >> Share

  302. KANG YJ, Oh SJ, Choi H, Cho S, et al
    Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06017.
    >> Share

  303. TZEKAKI EE, Geromichalos G, Lavrentiadou SN, Tsantarliotou MP, et al
    Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06054.
    >> Share

  304. SHLIAKHTUNOU YA
    CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06036.
    >> Share

  305. LEONE JP, Leone BA, Zwenger AO, Vallejo CT, et al
    The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06052.
    >> Share

  306. KLAESTAD E, Sawicka JE, Engstrom MJ, Ytterhus B, et al
    ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
    Breast Cancer Res Treat. 2021 Jan 2. pii: 10.1007/s10549-020-06035.
    >> Share

  307. VILLARREAL-GARZA C, Mesa-Chavez F, Garza-Ledezma MRA, Pena-Curiel O, et al
    Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention.
    Breast Cancer Res Treat. 2021;185:453-458.
    >> Share

  308. COX K, Dineen N, Taylor-Phillips S, Sharma N, et al
    Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relev
    Breast Cancer Res Treat. 2021;185:413-422.
    >> Share

  309. SADEGHALVAD M, Mohammadi-Motlagh HR, Rezaei N
    Immune microenvironment in different molecular subtypes of ductal breast carcinoma.
    Breast Cancer Res Treat. 2021;185:261-279.
    >> Share

  310. POLAT DS, Schopp JG, Arjmandi F, Porembka J, et al
    Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions.
    Breast Cancer Res Treat. 2021;185:479-494.
    >> Share

  311. APPELMAN L, Appelman PTM, Siebers CCN, Bult P, et al
    The value of mammography in women with focal breast complaints in addition to initial targeted ultrasound.
    Breast Cancer Res Treat. 2021;185:381-389.
    >> Share

  312. GALMOR L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, et al
    Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2021;185:391-399.
    >> Share

  313. MANNLE H, Siebers JW, Momm F, Munstedt K, et al
    Impact of patients' refusal to undergo adjuvant treatment measures on survival.
    Breast Cancer Res Treat. 2021;185:239-246.
    >> Share

  314. PONDE N, Agbor-Tarh D, Dal Lago L, Korde LA, et al
    Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
    Breast Cancer Res Treat. 2021;185:107-116.
    >> Share

  315. DENG J, Thennavan A, Shah S, Bagdatlioglu E, et al
    Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
    Breast Cancer Res Treat. 2021;185:85-94.
    >> Share

  316. TOUSSAINT A, Piaget-Rossel R, Stormacq C, Mathevet P, et al
    Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021;185:21-37.
    >> Share

  317. BAEK SY, Kim J, Chung IY, Ko BS, et al
    Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis.
    Breast Cancer Res Treat. 2021;185:155-164.
    >> Share

  318. SOMASUNDARAM SK, Potter S, Elgammal S, Maxwell AJ, et al
    Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire.
    Breast Cancer Res Treat. 2021;185:13-20.
    >> Share

    December 2020
  319. ALTUNDAG K
    Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients.
    Breast Cancer Res Treat. 2020;184:999.
    >> Share

    November 2020
  320. SCHIZA A, Mauri D, Fredriksson I, Anna-Karin Wennstig, et al
    Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
    Breast Cancer Res Treat. 2020 Nov 30. pii: 10.1007/s10549-020-06022.
    >> Share

  321. PING J, Huang S, Wu J, Bao P, et al
    Association between lincRNA expression and overall survival for patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Nov 27. pii: 10.1007/s10549-020-06021.
    >> Share

  322. SHAH C, Zambelli-Weiner A, Delgado N, Sier A, et al
    The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements.
    Breast Cancer Res Treat. 2020 Nov 27. pii: 10.1007/s10549-020-05988.
    >> Share

  323. PAK LM, Gaither R, Rosenberg SM, Ruddy KJ, et al
    Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    Breast Cancer Res Treat. 2020 Nov 26. pii: 10.1007/s10549-020-06027.
    >> Share

  324. BRAAL CL, Hussaarts KGAM, Seuren L, Oomen-deHoop E, et al
    Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
    Breast Cancer Res Treat. 2020 Nov 23. pii: 10.1007/s10549-020-05979.
    >> Share

  325. RICHMAN J, Ring A, Dowsett M, Sestak I, et al
    Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2020 Nov 21. pii: 10.1007/s10549-020-06013.
    >> Share

  326. CLIFTON K, Luo J, Tao Y, Saam J, et al
    Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
    Breast Cancer Res Treat. 2020 Nov 20. pii: 10.1007/s10549-020-06019.
    >> Share

  327. PRAKASH I, Thomas SM, Greenup RA, Plichta JK, et al
    Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
    Breast Cancer Res Treat. 2020 Nov 18. pii: 10.1007/s10549-020-06012.
    >> Share

  328. SACHDEV JC, Munster P, Northfelt DW, Han HS, et al
    Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
    Breast Cancer Res Treat. 2020 Nov 17. pii: 10.1007/s10549-020-05995.
    >> Share

  329. XIE E, Lapinski MM, Talamantes S, Nonyane BAS, et al
    Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Nov 13. pii: 10.1007/s10549-020-06016.
    >> Share

  330. CHOBRUTSKIY A, Chobrutskiy BI, Zaman S, Hsiang M, et al
    Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer.
    Breast Cancer Res Treat. 2020 Nov 12. pii: 10.1007/s10549-020-05996.
    >> Share

  331. TROPEE R, de la Pena Avalos B, Gough M, Snell C, et al
    The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer.
    Breast Cancer Res Treat. 2020 Nov 12. pii: 10.1007/s10549-020-05997.
    >> Share

  332. LUGTENBERG RT, de Groot S, Kaptein AA, Fischer MJ, et al
    Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial.
    Breast Cancer Res Treat. 2020 Nov 11. pii: 10.1007/s10549-020-05991.
    >> Share

  333. SAKHUJA S, Deveaux A, Wilson LE, Vin-Raviv N, et al
    Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset.
    Breast Cancer Res Treat. 2020 Nov 11. pii: 10.1007/s10549-020-06007.
    >> Share

  334. METCALFE KA, Candib A, Giannakeas V, Eisen A, et al
    The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Nov 10. pii: 10.1007/s10549-020-05992.
    >> Share

  335. PALLESCHI M, Iaia ML, Casadei C
    Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.
    Breast Cancer Res Treat. 2020 Nov 10. pii: 10.1007/s10549-020-06010.
    >> Share

  336. DAMIN AP, Zancan M, Melo MP, Biazus JV, et al
    Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Breast Cancer Res Treat. 2020 Nov 9. pii: 10.1007/s10549-020-06011.
    >> Share

  337. LIU S, Zeng S, Xia L, Yu M, et al
    Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.
    Breast Cancer Res Treat. 2020 Nov 9. pii: 10.1007/s10549-020-06015.
    >> Share

  338. ELSHARAWY KA, Althobiti M, Mohammed OJ, Aljohani AI, et al
    Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Nov 8. pii: 10.1007/s10549-020-05999.
    >> Share

  339. SHAH H, Surujballi J, Awan AA, Hutton B, et al
    A scoping review characterizing "Choosing Wisely(R)" recommendations for breast cancer management.
    Breast Cancer Res Treat. 2020 Nov 6. pii: 10.1007/s10549-020-06009.
    >> Share

  340. DAHLMAN D, Magnusson H, Li X, Sundquist J, et al
    Drug use disorder and risk of incident and fatal breast cancer: a nationwide epidemiological study.
    Breast Cancer Res Treat. 2020 Nov 6. pii: 10.1007/s10549-020-05998.
    >> Share

  341. KOPPELMANS V, van der Willik KD, Aleman BMP, van Leeuwen FE, et al
    Long-term effects of adjuvant treatment for breast cancer on carotid plaques and brain perfusion.
    Breast Cancer Res Treat. 2020 Nov 5. pii: 10.1007/s10549-020-05990.
    >> Share

  342. SELLA T, Gelber SI, Poorvu PD, Kim HJ, et al
    Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2020 Nov 4. pii: 10.1007/s10549-020-05989.
    >> Share

  343. CADILI L, DeGirolamo K, McKevitt E, Brown CJ, et al
    COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic.
    Breast Cancer Res Treat. 2020 Nov 4. pii: 10.1007/s10549-020-06008.
    >> Share

  344. SOPIK V
    International variation in breast cancer incidence and mortality in young women.
    Breast Cancer Res Treat. 2020 Nov 3. pii: 10.1007/s10549-020-06003.
    >> Share

  345. CHEN X, Guo K, Lin J
    Letter to the editor regarding the article "Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer".
    Breast Cancer Res Treat. 2020 Nov 2. pii: 10.1007/s10549-020-05987.
    >> Share

  346. HU X, Myers KS, Oluyemi ET, Philip M, et al
    Presentation and characteristics of breast cancer in young women under age 40.
    Breast Cancer Res Treat. 2020 Nov 2. pii: 10.1007/s10549-020-06000.
    >> Share

    October 2020
  347. WEN Y, Wu X, Peng H, Li C, et al
    Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis.
    Breast Cancer Res Treat. 2020 Oct 31. pii: 10.1007/s10549-020-05973.
    >> Share

  348. KOYUNCU D, Sharma U, Goka ET, Lippman ME, et al
    Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.
    Breast Cancer Res Treat. 2020 Oct 31. pii: 10.1007/s10549-020-05962.
    >> Share

  349. USISKIN I, Li F, Irwin ML, Cartmel B, et al
    Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2020 Oct 30. pii: 10.1007/s10549-020-05994.
    >> Share

  350. FINDLAY-SHIRRAS L, Lima I, Smith G, Clemons M, et al
    Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study.
    Breast Cancer Res Treat. 2020 Oct 30. pii: 10.1007/s10549-020-05965.
    >> Share

  351. SHAIK AN, Kiavash K, Stark K, Boerner JL, et al
    Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women.
    Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05983.
    >> Share

  352. LATTIMORE V, Parsons MT, Spurdle AB, Pearson J, et al
    Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
    Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05986.
    >> Share

  353. DACKUS GMHE, Jozwiak K, van der Wall E, van Diest PJ, et al
    Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
    Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05978.
    >> Share

  354. ZHAO F, Copley B, Niu Q, Liu F, et al
    Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
    Breast Cancer Res Treat. 2020 Oct 27. pii: 10.1007/s10549-020-05984.
    >> Share

  355. HERBERT SL, Wockel A, Kreienberg R, Kuhn T, et al
    To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
    Breast Cancer Res Treat. 2020 Oct 26. pii: 10.1007/s10549-020-05974.
    >> Share

  356. BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
    A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Oct 22. pii: 10.1007/s10549-020-05976.
    >> Share

  357. KARIRI YA, Alsaleem M, Joseph C, Alsaeed S, et al
    The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05955.
    >> Share

  358. SIMONS JM, Jacobs JG, Roijers JP, Beek MA, et al
    Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
    Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05966.
    >> Share

  359. WEISER R, Haque W, Polychronopoulou E, Hatch SS, et al
    The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
    Breast Cancer Res Treat. 2020 Oct 18. pii: 10.1007/s10549-020-05971.
    >> Share

  360. GARCIA-TEJEDOR A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, et al
    Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
    Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05970.
    >> Share

  361. SIM EJ, Ko KP, Ahn C, Park SM, et al
    Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05875.
    >> Share

  362. LU YC, Huang DW, Chen PT, Tsai CF, et al
    Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study.
    Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05969.
    >> Share

  363. BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
    A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05960.
    >> Share

  364. KUMAR R, Kuligina E, Sokolenko A, Siddiqui Q, et al
    Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-beta/SMAD signaling.
    Breast Cancer Res Treat. 2020 Oct 15. pii: 10.1007/s10549-020-05958.
    >> Share

  365. ZHOU M, Venkata PP, Viswanadhapalli S, Palacios B, et al
    KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05963.
    >> Share

  366. WU ZY, Kim N, Ko B
    Tumor localization for breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05950.
    >> Share

  367. TURNBULL AK, Patel S, Martinez-Perez C, Rigg A, et al
    Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer.
    Breast Cancer Res Treat. 2020 Oct 12. pii: 10.1007/s10549-020-05951.
    >> Share

  368. BEN-ZION BERLINER M, Yerushalmi R, Lavie I, Benouaich-Amiel A, et al
    Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
    Breast Cancer Res Treat. 2020 Oct 10. pii: 10.1007/s10549-020-05959.
    >> Share

  369. HATONO M, Ikeda H, Suzuki Y, Kajiwara Y, et al
    Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments.
    Breast Cancer Res Treat. 2020 Oct 9. pii: 10.1007/s10549-020-05957.
    >> Share

  370. PESCE C, Jaffe J, Kuchta K, Yao K, et al
    Patient-reported outcomes among women with unilateral breast cancer undergoing breast conservation versus single or double mastectomy.
    Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05964.
    >> Share

  371. ABRAHAM HG, Xia Y, Mukherjee B, Merajver SD, et al
    Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database.
    Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05938.
    >> Share

  372. FILHO OM, Giobbie-Hurder A, Lin NU, Faggen M, et al
    A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05928.
    >> Share

  373. GOYAL A, Puri S, Marshall A, Valassiadou K, et al
    A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients.
    Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05961.
    >> Share

  374. PARK JW, Han K, Shin DW, Yeo Y, et al
    Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women.
    Breast Cancer Res Treat. 2020 Oct 3. pii: 10.1007/s10549-020-05952.
    >> Share

  375. KOELMEYER LA, Moloney E, Boyages J, Sherman KA, et al
    Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05953.
    >> Share

  376. YAN S, Dey P, Ziegler Y, Jiao X, et al
    Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05948.
    >> Share

  377. LAI V, Hajjaj O, Le D, Shokoohi A, et al
    Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05894.
    >> Share

    September 2020
  378. VAN RAEMDONCK E, Floris G, Berteloot P, Laenen A, et al
    Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Sep 27. pii: 10.1007/s10549-020-05935.
    >> Share

  379. JIANG YZ, Ge LP, Jin X, Fan L, et al
    Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
    Breast Cancer Res Treat. 2020 Sep 25. pii: 10.1007/s10549-020-05940.
    >> Share

  380. HERNANZ F
    Comments on patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05945.
    >> Share

  381. MOHAMADZADE Z, Mahjoubi F, Soltani BM
    Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05937.
    >> Share

  382. ZAHL PH, Kristiansen IS
    Re: Stage-specific survival has improved for young breast cancer patients since 2000: but not equally?
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05941.
    >> Share

  383. ABDEL-RAZEQ H, Edaily S, Iweir S, Salam M, et al
    Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05942.
    >> Share

  384. MARSH S, Borges VF, Coons HL, Afghahi A, et al
    Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers.
    Breast Cancer Res Treat. 2020 Sep 23. pii: 10.1007/s10549-020-05880.
    >> Share

  385. JACOBSE JN, Schaapveld M, Boekel NB, Hooning MJ, et al
    Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
    Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05930.
    >> Share

  386. NICHOLS HB, Graff M, Bensen JT, Lunetta KL, et al
    Genetic variants in anti-Mullerian hormone-related genes and breast cancer risk: results from the AMBER consortium.
    Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05944.
    >> Share

  387. JERZAK KJ, Lohmann AE, Ennis M, Nemeth E, et al
    Prognostic associations of plasma hepcidin in women with early breast cancer.
    Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05903.
    >> Share

  388. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan.
    Breast Cancer Res Treat. 2020 Sep 19. pii: 10.1007/s10549-020-05934.
    >> Share

  389. TIAINEN S, Rilla K, Hamalainen K, Oikari S, et al
    The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype.
    Breast Cancer Res Treat. 2020 Sep 18. pii: 10.1007/s10549-020-05925.
    >> Share

  390. GEBREMARIAM A, Dereje N, Addissie A, Worku A, et al
    Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia.
    Breast Cancer Res Treat. 2020 Sep 18. pii: 10.1007/s10549-020-05919.
    >> Share

  391. XUE L, Chen F, Yue F, Camacho L, et al
    Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05927.
    >> Share

  392. DENT SF, Botros J, Rushton M, Aseyev O, et al
    Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
    Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05887.
    >> Share

  393. LOSK K, Freedman RA, Laws A, Kantor O, et al
    Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
    Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05931.
    >> Share

  394. WANG B, Huang T, Fang Q, Zhang X, et al
    Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis.
    Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05904.
    >> Share

  395. VAN NIJNATTEN TJA, van Tiel LPT, Voogd AC, Groothuis-Oudshoorn CGM, et al
    The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study.
    Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05906.
    >> Share

  396. GOLDFARB SB, Turan V, Bedoschi G, Taylan E, et al
    Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
    Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05933.
    >> Share

  397. PALLESCHI M, Scarpi E, Casadei C
    Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05923.
    >> Share

  398. MONTAGNA E, Pagan E, Bagnardi V, Colleoni M, et al
    Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05900.
    >> Share

  399. HAN Y, Miao ZF, Lian M, Peterson LL, et al
    Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05902.
    >> Share

  400. KOU K, Cameron J, Aitken JF, Youl P, et al
    Factors associated with being diagnosed with high severity of breast cancer: a population-based study in Queensland, Australia.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05905.
    >> Share

  401. ABDELHAFEZ AH, Musall BC, Adrada BE, Hess K, et al
    Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05917.
    >> Share

  402. TAKAHASHI M, Ohtani S, Nagai SE, Takashima S, et al
    The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
    Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05921.
    >> Share

  403. MENEVEAU MO, Keim-Malpass J, Camacho TF, Anderson RT, et al
    Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05908.
    >> Share

  404. FRISELL A, Lagergren J, Halle M, de Boniface J, et al
    Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05911.
    >> Share

  405. VOGSEN M, Jensen JD, Christensen IY, Gerke O, et al
    FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05929.
    >> Share

  406. LIN Y, Lin L, Fu F, Wang C, et al
    Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05916.
    >> Share

  407. YUSUFOV M, Nathan M, Wiley A, Russell J, et al
    Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05920.
    >> Share

  408. MAO D, Hachem H, Chang H, Dima D, et al
    Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05892.
    >> Share

  409. CALIP GS, Kidd J, Bernhisel R, Cox HC, et al
    Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
    Breast Cancer Res Treat. 2020 Sep 11. pii: 10.1007/s10549-020-05922.
    >> Share

  410. HISOSHIMA M, Urano M, Ohashi K, Ogawa M, et al
    Utility of 70-kV single-energy CT in depicting the extent of breast cancer for preoperative planning.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05909.
    >> Share

  411. XING CY, Doose M, Qin B, Lin Y, et al
    Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05901.
    >> Share

  412. YANG Y, Zhao J, Mao Y, Lin G, et al
    UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing beta-catenin.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05899.
    >> Share

  413. SOLLENA P, Nikolaou V, Soupos N, Kotteas E, et al
    Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05914.
    >> Share

  414. LEE KT, Jacobs L, Walsh EM, Stearns V, et al
    Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05910.
    >> Share

  415. DE REZENDE LF, Francisco VE, Franco RL
    Telerehabilitation for patients with breast cancer through the COVID-19 pandemic.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05926.
    >> Share

  416. CHA C, Lee J, Kim D, Park S, et al
    Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Sep 9. pii: 10.1007/s10549-020-05907.
    >> Share

  417. SUN Y, Li Y, Wu J, Tian H, et al
    Nomograms for prediction of overall and cancer-specific survival in young breast cancer.
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05870.
    >> Share

  418. CHEN R, Ma G, Xia T
    Letter to the editor with regard to the manuscript titled "Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy".
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05886.
    >> Share

  419. KO NY, Qureshi MM, Oladeru OT, Cassidy MR, et al
    Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05888.
    >> Share

  420. ZHANG Y, Liu J, Raj-Kumar PK, Sturtz LA, et al
    Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05884.
    >> Share

  421. GONZALEZ-SANTIAGO S, Saura C, Ciruelos E, Alonso JL, et al
    Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05866.
    >> Share

  422. SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
    Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05864.
    >> Share

  423. NIETZ S, O'Neil DS, Ayeni O, Chen WC, et al
    A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.
    Breast Cancer Res Treat. 2020 Sep 1. pii: 10.1007/s10549-020-05889.
    >> Share

  424. GUVAKOVA MA, Prabakaran I, Wu Z, Hoffman DI, et al
    CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2020;183:333-346.
    >> Share

  425. BROWNE JL, Korsun N, Casas L, Rodriguez I, et al
    "Are changes in breast density during the menstrual cycle relevant? To what?"
    Breast Cancer Res Treat. 2020;183:451-458.
    >> Share

  426. KAIDAR-PERSON O, Poortmans P, Offersen BV, Siesling S, et al
    Spatial location of local recurrences after mastectomy: a systematic review.
    Breast Cancer Res Treat. 2020;183:263-273.
    >> Share

  427. WONG EC, Kaplan CP, Barulich M, Melisko M, et al
    Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center.
    Breast Cancer Res Treat. 2020;183:381-389.
    >> Share

  428. JUNG JJ, Kang E, Kim EK, Kim SM, et al
    External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.
    Breast Cancer Res Treat. 2020;183:373-380.
    >> Share

  429. LI K, Liao N, Chen B, Zhang G, et al
    Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
    Breast Cancer Res Treat. 2020;183:321-332.
    >> Share

  430. HENDRIKS MP, Verbeek XAAM, van Manen JG, van der Heijden SE, et al
    Clinical decision trees support systematic evaluation of multidisciplinary team recommendations.
    Breast Cancer Res Treat. 2020;183:355-363.
    >> Share

  431. GOEL AK, Zamre V, Hari S
    Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.
    Breast Cancer Res Treat. 2020;183:489-490.
    >> Share

    August 2020
  432. LYNGE E, Beau AB, von Euler-Chelpin M, Napolitano G, et al
    Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark.
    Breast Cancer Res Treat. 2020 Aug 30. pii: 10.1007/s10549-020-05896.
    >> Share

  433. HOWELL SJ, Coe F, Wang X, Horsley L, et al
    Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
    Breast Cancer Res Treat. 2020 Aug 29. pii: 10.1007/s10549-020-05868.
    >> Share

  434. KIM JY, Park K, Im SA, Jung KH, et al
    Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
    Breast Cancer Res Treat. 2020 Aug 28. pii: 10.1007/s10549-020-05891.
    >> Share

  435. ERBER R, Rubner M, Davenport S, Hauke S, et al
    Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 27. pii: 10.1007/s10549-020-05865.
    >> Share

  436. PIZZATO M, Carioli G, Rosso S, Zanetti R, et al
    The impact of selected risk factors among breast cancer molecular subtypes: a case-only study.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05820.
    >> Share

  437. HERMANN N, Klil-Drori A, Angarita FA, Westergard S, et al
    Screening women at high risk for breast cancer: one program fits all? : Subgroup analysis of a large population high risk breast screening program.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05895.
    >> Share

  438. SUNDBOLL J, Farkas DK, Adelborg K, Schapira L, et al
    Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05879.
    >> Share

  439. TRANT AA, Walz L, Allen W, DeJesus J, et al
    Increasing accrual of minority patients in breast cancer clinical trials.
    Breast Cancer Res Treat. 2020 Aug 25. pii: 10.1007/s10549-020-05873.
    >> Share

  440. OGIYA R, Niikura N, Kumamaru H, Takeuchi Y, et al
    Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.
    Breast Cancer Res Treat. 2020 Aug 20. pii: 10.1007/s10549-020-05869.
    >> Share

  441. RIEDEL F, Heil J, Feisst M, Moderow M, et al
    Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Breast Cancer Res Treat. 2020 Aug 20. pii: 10.1007/s10549-020-05876.
    >> Share

  442. DE BOER AZ, van de Water W, Bastiaannet E, de Glas NA, et al
    Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.
    Breast Cancer Res Treat. 2020 Aug 19. pii: 10.1007/s10549-020-05860.
    >> Share

  443. KIM JY, Jung HH, Sohn I, Woo SY, et al
    Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05874.
    >> Share

  444. KILBREATH SL, Ward LC, Davis GM, Degnim AC, et al
    Reduction of breast lymphoedema secondary to breast cancer: a randomised controlled exercise trial.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05863.
    >> Share

  445. DIXON JM, Grewar J, Twelves D, Graham A, et al
    Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05843.
    >> Share

  446. BAGHERZADEH M, Szymiczek A, Donenberg T, Butler R, et al
    Association of RAD51C germline mutations with breast cancer among Bahamians.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05872.
    >> Share

  447. KAZMI S, Chatterjee D, Raju D, Hauser R, et al
    Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
    Breast Cancer Res Treat. 2020 Aug 17. pii: 10.1007/s10549-020-05867.
    >> Share

  448. TEODOZIO CGC, Marchito LO, Fabro EAN, Macedo FO, et al
    Shoulder amplitude movement does not influence postoperative wound complications after breast cancer surgery: a randomized clinical trial.
    Breast Cancer Res Treat. 2020 Aug 17. pii: 10.1007/s10549-020-05826.
    >> Share

  449. CAVALCANTE FP, Novita GG, Millen EC, Zerwes FP, et al
    Management of early breast cancer during the COVID-19 pandemic in Brazil.
    Breast Cancer Res Treat. 2020 Aug 16. pii: 10.1007/s10549-020-05877.
    >> Share

  450. BRAAL CL, Hussaarts KGAM, Seuren L, Oomen-de Hoop E, et al
    Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
    Breast Cancer Res Treat. 2020 Aug 16. pii: 10.1007/s10549-020-05829.
    >> Share

  451. GEORGE MA, Lustberg MB, Orchard TS
    Psychoneurological symptom cluster in breast cancer: the role of inflammation and diet.
    Breast Cancer Res Treat. 2020 Aug 15. pii: 10.1007/s10549-020-05808.
    >> Share

  452. LIANG R
    Letter to the editor Re: Pan et al. "LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer".
    Breast Cancer Res Treat. 2020 Aug 14. pii: 10.1007/s10549-020-05853.
    >> Share

  453. DIAMOND JR, Becerra C, Richards D, Mita A, et al
    Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Aug 14. pii: 10.1007/s10549-020-05817.
    >> Share

  454. BARTLETT DB, Broadwater G, White HK, Shelby R, et al
    Factors associated with falls in older women with breast cancer: the use of a brief geriatric screening tool in clinic.
    Breast Cancer Res Treat. 2020 Aug 13. pii: 10.1007/s10549-020-05862.
    >> Share

  455. D'HONDT C, Vanhoeij M, Van Moer E, Segers I, et al
    Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Aug 13. pii: 10.1007/s10549-020-05858.
    >> Share

  456. RUGO HS, Dieras V, Cortes J, Patt D, et al
    Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
    Breast Cancer Res Treat. 2020 Aug 12. pii: 10.1007/s10549-020-05838.
    >> Share

  457. KANJANAPAN Y, Lok SW, Gibbs P, De Boer R, et al
    Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05825.
    >> Share

  458. CADY B, Fulton JP
    57% decline in Rhode Island invasive breast cancer mortality between 1987 and 2017: mammography predominates in preventing mortality.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05834.
    >> Share

  459. ZHANG Y, Dian L, Wei X, Huang J, et al
    Physicians' attitudes towards reproduction in young patients with early breast cancer in China.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05854.
    >> Share

  460. BI Z, Chen P, Liu YB, Zhao T, et al
    Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05851.
    >> Share

  461. SOKOLENKO AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, et al
    Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05827.
    >> Share

  462. CRYSTAL JS, Rand J, Johnson J, Kim S, et al
    Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05823.
    >> Share

  463. PAPAUTSKY EL, Hamlish T
    Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05828.
    >> Share

  464. TREVINO KM, Iyengar N, Li Q, Mao JJ, et al
    Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05859.
    >> Share

  465. CHEN J, Lai YH, Ooi S, Song Y, et al
    BTB domain-containing 7 predicts low recurrence and suppresses tumor progression by deactivating Notch1 signaling in breast cancer.
    Breast Cancer Res Treat. 2020 Aug 8. pii: 10.1007/s10549-020-05857.
    >> Share

  466. SCHETTINI F, Sobhani N, Ianza A, Triulzi T, et al
    Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
    Breast Cancer Res Treat. 2020 Aug 7. pii: 10.1007/s10549-020-05856.
    >> Share

  467. WILLIAMS CB, Nebhan CA, Yang J, Starnes LS, et al
    Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
    Breast Cancer Res Treat. 2020 Aug 7. pii: 10.1007/s10549-020-05846.
    >> Share

  468. SALTBAEK L, Horsboel TA, Offersen BV, Andersson M, et al
    Patterns in detection of recurrence among patients treated for breast cancer.
    Breast Cancer Res Treat. 2020 Aug 6. pii: 10.1007/s10549-020-05847.
    >> Share

  469. PATEL MA, Shah JL, Abrahamse PH, Jagsi R, et al
    A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Aug 5. pii: 10.1007/s10549-020-05844.
    >> Share

  470. ZHOU YT, Zheng LY, Wang YJ, Yang L, et al
    Effect of functional variant rs11466313 on breast cancer susceptibility and TGFB1 promoter activity.
    Breast Cancer Res Treat. 2020 Aug 5. pii: 10.1007/s10549-020-05841.
    >> Share

  471. SKRIVER SK, Jensen MB, Eriksen JO, Ahlborn LB, et al
    Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 3. pii: 10.1007/s10549-020-05833.
    >> Share

  472. SPECHT M, Sobti N, Rosado N, Tomczyk E, et al
    High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis.
    Breast Cancer Res Treat. 2020;182:679-688.
    >> Share

  473. GAO W, Zeng Y, Fei X, Chen X, et al
    Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05842.
    >> Share

  474. ZEIDMAN M, Alberty-Oller JJ, Ru M, Pisapati KV, et al
    Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05809.
    >> Share

  475. AOYAGI K, Higuchi Y, Matsunaga S, Serizawa T, et al
    Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702).
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05835.
    >> Share

  476. JOONA TB, Digkas E, Wennstig AK, Nystrom K, et al
    Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05815.
    >> Share

  477. SANDERINK WBG, Strobbe LJA, Bult P, Schlooz-Vries MS, et al
    Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05814.
    >> Share

  478. KOPPARTHY P, Daily K
    A case for Tamoxifen with ovarian function suppression.
    Breast Cancer Res Treat. 2020;183:241-242.
    >> Share

  479. AZAM S, Jacobsen KK, Aro AR, Lynge E, et al
    Hormone replacement therapy and mammographic density: a systematic literature review.
    Breast Cancer Res Treat. 2020;182:555-579.
    >> Share

  480. ABBATE O, Rosado N, Sobti N, Vieira BL, et al
    Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes.
    Breast Cancer Res Treat. 2020;182:543-554.
    >> Share

  481. LEEVAN E, Ho BT, Seto S, Shen J, et al
    Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.
    Breast Cancer Res Treat. 2020;183:145-151.
    >> Share

  482. NAOUM GE, Oladeru OT, Niemierko A, Salama L, et al
    Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
    Breast Cancer Res Treat. 2020;183:127-136.
    >> Share

  483. LIU D
    Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Breast Cancer Res Treat. 2020;183:95-105.
    >> Share

    July 2020
  484. HULL O, Niranjan SJ, Wallace AS, Williams BR, et al
    Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 31. pii: 10.1007/s10549-020-05832.
    >> Share

  485. HOTTON J, Salleron J, Henrot P, Buhler J, et al
    Pre-operative axillary ultrasound with fine-needle aspiration cytology performance and predictive factors of false negatives in axillary lymph node involvement in early breast cancer.
    Breast Cancer Res Treat. 2020 Jul 31. pii: 10.1007/s10549-020-05830.
    >> Share

  486. AL AMRI WS, Baxter DE, Hanby AM, Stead LF, et al
    Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants.
    Breast Cancer Res Treat. 2020 Jul 30. pii: 10.1007/s10549-020-05836.
    >> Share

  487. AKS R, Peleg Hasson S, Sivan A, Kohen T, et al
    Diagnostic workup of early-stage breast cancer: can we choose more wisely?
    Breast Cancer Res Treat. 2020 Jul 29. pii: 10.1007/s10549-020-05813.
    >> Share

  488. ROSA DD, Bines J, Werutsky G, Barrios CH, et al
    The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).
    Breast Cancer Res Treat. 2020 Jul 29. pii: 10.1007/s10549-020-05831.
    >> Share

  489. CHAINITIKUN S, Long JP, Rodriguez-Bautista R, Iwase T, et al
    The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 27. pii: 10.1007/s10549-020-05837.
    >> Share

  490. HARDER H, Shilling VM, May SF, Cella D, et al
    The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 27. pii: 10.1007/s10549-020-05798.
    >> Share

  491. WANG L, He Y, Li J, Wang T, et al
    Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method.
    Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05821.
    >> Share

  492. ZHAO J, Meisel J, Guo Y, Nahta R, et al
    Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05819.
    >> Share

  493. KIM SH, Ahn S, Suh KJ, Kim YJ, et al
    Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05811.
    >> Share

  494. SMITH BL, Nguyen A, Korotkin JE, Kelly BN, et al
    A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
    Breast Cancer Res Treat. 2020 Jul 25. pii: 10.1007/s10549-020-05792.
    >> Share

  495. TAHIRI A, Tekpli X, Satheesh SV, DeWijn R, et al
    Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 24. pii: 10.1007/s10549-020-05763.
    >> Share

  496. DUDEK AZ, Liu LC, Fischer JH, Wiley EL, et al
    Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
    Breast Cancer Res Treat. 2020 Jul 22. pii: 10.1007/s10549-020-05787.
    >> Share

  497. KARLSSON F, Granath F, Smedby KE, Zedenius J, et al
    Sarcoma of the breast: breast cancer history as etiologic and prognostic factor-A population-based case-control study.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05802.
    >> Share

  498. CHEPIKOVA OE, Malin D, Strekalova E, Lukasheva EV, et al
    Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05801.
    >> Share

  499. YAP NY, Tan NYT, Tan CJ, Loh KW, et al
    Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05807.
    >> Share

  500. FASANO J, Shao T, Huang HH, Kessler AJ, et al
    Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05800.
    >> Share

  501. MINAMI CA, King TA, Mittendorf EA
    Patient preferences for locoregional therapy in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05737.
    >> Share

  502. SCHAIRER C, Laurent CA, Moy LM, Gierach GL, et al
    Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05785.
    >> Share

  503. BORTNIK S, Tessier-Cloutier B, Leung S, Xu J, et al
    Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05795.
    >> Share

  504. FINN RS, Boer K, Bondarenko I, Patel R, et al
    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
    Breast Cancer Res Treat. 2020 Jul 18. pii: 10.1007/s10549-020-05755.
    >> Share

  505. ARABANDI P, Slade AN, Sutton AL, McGuire KP, et al
    Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jul 16. pii: 10.1007/s10549-020-05784.
    >> Share

  506. MOFTAKHAR B, Lekkala M, Strawderman M, Smith TC, et al
    Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 15. pii: 10.1007/s10549-020-05793.
    >> Share

  507. REN H, Mi X, Zhao P, Zhao X, et al
    TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of beta-catenin.
    Breast Cancer Res Treat. 2020 Jul 15. pii: 10.1007/s10549-020-05789.
    >> Share

  508. HAM A, Kim MH, Kim GM, Kim JH, et al
    Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 14. pii: 10.1007/s10549-020-05796.
    >> Share

  509. BYRD BK, Krishnaswamy V, Gui J, Rooney T, et al
    The shape of breast cancer.
    Breast Cancer Res Treat. 2020 Jul 12. pii: 10.1007/s10549-020-05780.
    >> Share

  510. MCEVOY AM, Poplack S, Nickel K, Olsen MA, et al
    Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
    Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05768.
    >> Share

  511. MISRA S, Lee G, Korzets Y, Wang L, et al
    Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation.
    Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05781.
    >> Share

  512. SANT M, Meneghini E, Bastos J, Rossi PG, et al
    Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study.
    Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05761.
    >> Share

  513. DU ZL, Wang Y, Wang DY, Zhang L, et al
    Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
    Breast Cancer Res Treat. 2020 Jul 9. pii: 10.1007/s10549-020-05776.
    >> Share

  514. THEIN KZ, Htut TW, Ball S, Swarup S, et al
    Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of rand
    Breast Cancer Res Treat. 2020 Jul 9. pii: 10.1007/s10549-020-05783.
    >> Share

  515. ALTER BP, Best AF
    Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2020 Jul 8. pii: 10.1007/s10549-020-05775.
    >> Share

  516. STOCKER A, Trojan A, Elfgen C, Hilbers ML, et al
    Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 7. pii: 10.1007/s10549-020-05772.
    >> Share

  517. BORRIE AE, Rose FA, Choi YH, Perera FE, et al
    Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
    Breast Cancer Res Treat. 2020 Jul 6. pii: 10.1007/s10549-020-05777.
    >> Share

  518. WHITAKER KD, Sheth D, Olopade OI
    Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
    Breast Cancer Res Treat. 2020 Jul 3. pii: 10.1007/s10549-020-05759.
    >> Share

  519. CRISCITIELLO C, Vingiani A, Maisonneuve P, Viale G, et al
    Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
    Breast Cancer Res Treat. 2020 Jul 3. pii: 10.1007/s10549-020-05771.
    >> Share

  520. WALTER V, Fischer C, Deutsch TM, Ersing C, et al
    Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 1. pii: 10.1007/s10549-020-05746.
    >> Share

  521. VAN STEENHOVEN JEC, den Dekker BM, Kuijer A, van Diest PJ, et al
    Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
    Breast Cancer Res Treat. 2020;182:107-115.
    >> Share

  522. RAMZI S, Najeeb E, Coulthard J, Jenkins S, et al
    Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
    Breast Cancer Res Treat. 2020;182:47-54.
    >> Share

  523. DOFARA SG, Chang SL, Diorio C
    Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features.
    Breast Cancer Res Treat. 2020;182:169-179.
    >> Share

  524. PASZAT L, Sutradhar R, Rakovitch E
    The impact of ductal carcinoma in situ on health services utilization.
    Breast Cancer Res Treat. 2020;182:159-168.
    >> Share

  525. WATANABE T, Honda T, Totsuka H, Yoshida M, et al
    Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Breast Cancer Res Treat. 2020;182:491-502.
    >> Share

  526. MISRA S, Lee G, Maganti M, Koch CA, et al
    Utilization patterns and temporal trends of internal mammary nodal irradiation at a tertiary cancer center.
    Breast Cancer Res Treat. 2020;182:367-379.
    >> Share

  527. PALVE JS, Luukkaala TH, Kaariainen MT
    Predictive risk factors of complications in different breast reconstruction methods.
    Breast Cancer Res Treat. 2020;182:345-354.
    >> Share

  528. IWAMOTO T, Hara F, Uemura Y, Mukai H, et al
    NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
    Breast Cancer Res Treat. 2020;182:325-332.
    >> Share

  529. HASSAN Z, Boulos F, Abbas J, El Charif MH, et al
    Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes.
    Breast Cancer Res Treat. 2020;182:317-323.
    >> Share

  530. LEE MK, Sanaiha Y, Kusske AM, Thompson CK, et al
    A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers.
    Breast Cancer Res Treat. 2020;182:299-303.
    >> Share

  531. ANGARITA FA, Acuna SA, Cordeiro E, McCready DR, et al
    Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database.
    Breast Cancer Res Treat. 2020;182:429-438.
    >> Share

  532. CRAGUN D, Weidner A, Tezak A, Clouse K, et al
    Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Breast Cancer Res Treat. 2020;182:421-428.
    >> Share

    June 2020
  533. GUO D, Hendryx M, Liang X, Manson JE, et al
    Association between selenium intake and breast cancer risk: results from the Women's Health Initiative.
    Breast Cancer Res Treat. 2020 Jun 30. pii: 10.1007/s10549-020-05764.
    >> Share

  534. WANG DG, Barrios DM, Blinder VS, Bromberg JF, et al
    Dermatologic adverse events related to the PI3Kalpha inhibitor alpelisib (BYL719) in patients with breast cancer.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05726.
    >> Share

  535. KHALEFA HG, Shawki MA, Aboelhassan R, El Wakeel LM, et al
    Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05762.
    >> Share

  536. YANG X, Zhao L, Pei J, Wang Z, et al
    CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05753.
    >> Share

  537. CHEN FM, Huang LJ, Ou-Yang F, Kan JY, et al
    Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05729.
    >> Share

  538. DONAHUE PMC, Crescenzi R, Lee C, Garza M, et al
    Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05765.
    >> Share

  539. PERACHINO M, Poggio F, Lambertini M
    Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
    Breast Cancer Res Treat. 2020 Jun 28. pii: 10.1007/s10549-020-05767.
    >> Share

  540. YAO J, Liu Y, Cheng J
    Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China.
    Breast Cancer Res Treat. 2020 Jun 27. pii: 10.1007/s10549-020-05743.
    >> Share

  541. ACCORDINO MK, Wright JD, Buono D, Lin A, et al
    Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data.
    Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05756.
    >> Share

  542. HACKSHAW MD, Danysh HE, Singh J, Ritchey ME, et al
    Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05754.
    >> Share

  543. CAVAZZA M, Banks H, Ercolanoni M, Cukaj G, et al
    Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05748.
    >> Share

  544. STASZEWSKY L, Robusto F, Lepore V, Bisceglia L, et al
    Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study.
    Breast Cancer Res Treat. 2020 Jun 25. pii: 10.1007/s10549-020-05758.
    >> Share

  545. HAM A, Kim MH, Kim GM, Kim JH, et al
    Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05750.
    >> Share

  546. STARKINGS R, Shilling V, Jenkins V, Fallowfield L, et al
    A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05741.
    >> Share

  547. VERMA R, Hanby AM, Horgan K, Verghese ET, et al
    Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05757.
    >> Share

  548. WEI Y, Wang X, Zhang Z, Zhao C, et al
    Impact of NR5A2 and RYR2 3'UTR polymorphisms on the risk of breast cancer in a Chinese Han population.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05736.
    >> Share

  549. ROBERTSON S, Acs B, Lippert M, Hartman J, et al
    Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05752.
    >> Share

  550. HARBORG S, Heide-Jorgensen U, Ahern TP, Ewertz M, et al
    Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05749.
    >> Share

  551. HORIMOTO Y, Sasahara N, Sasaki R, Hlaing MT, et al
    High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05751.
    >> Share

  552. XU B, Li W, Zhang Q, Shao Z, et al
    Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
    Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05728.
    >> Share

  553. CHENG AS, Leung SCY, Gao D, Burugu S, et al
    Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05745.
    >> Share

  554. CHAMBERLIN MD, Wells JD, Shee K, Bean JR, et al
    Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05714.
    >> Share

  555. HOWLADER NR, Rahman MM, Hossain MA, Sultana R, et al
    Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05738.
    >> Share

  556. KAR A, Koto K, Walker D, Trudeau T, et al
    ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR(+)HER2(+) breast cancer patients.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05734.
    >> Share

  557. BESIC N, Smrekar J, Strazisar B
    Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study.
    Breast Cancer Res Treat. 2020 Jun 18. pii: 10.1007/s10549-020-05713.
    >> Share

  558. OBENG-GYASI S, Oppong B, Paskett ED, Lustberg M, et al
    Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?
    Breast Cancer Res Treat. 2020 Jun 16. pii: 10.1007/s10549-020-05740.
    >> Share

  559. AHMED M
    The bottom line for lesion localization in breast cancer.
    Breast Cancer Res Treat. 2020 Jun 13. pii: 10.1007/s10549-020-05735.
    >> Share

  560. TOLLOSA DN, Holliday E, Hure A, Tavener M, et al
    A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer.
    Breast Cancer Res Treat. 2020 Jun 13. pii: 10.1007/s10549-020-05704.
    >> Share

  561. HOLMES DR
    Breast cancer care during a pandemic: an opportune time for cryoablation?
    Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05724.
    >> Share

  562. RO EJ, Ryu SH, Park EY, Ryu JW, et al
    PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05732.
    >> Share

  563. O'KEEFE TJ, Wallace AM
    Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis.
    Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05733.
    >> Share

  564. ZHANG J, Lin M, Jin Y, Gu L, et al
    Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05730.
    >> Share

  565. HEEG E, Jensen MB, Mureau MAM, Ejlertsen B, et al
    Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05725.
    >> Share

  566. ALTHOBITI M, Muftah AA, Aleskandarany MA, Joseph C, et al
    The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05719.
    >> Share

  567. TZIKAS AK, Nemes S, Linderholm BK
    A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05727.
    >> Share

  568. ALEIXO GFP, Shachar SS, Deal AM, Nyrop KA, et al
    The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2020 Jun 9. pii: 10.1007/s10549-020-05731.
    >> Share

  569. AKHTAR Z, Stearns V, Cartwright P, Blackford AL, et al
    The effect of 1-day multidisciplinary clinic on breast cancer treatment.
    Breast Cancer Res Treat. 2020 Jun 8. pii: 10.1007/s10549-020-05721.
    >> Share

  570. VIDT ME, Potochny J, Dodge D, Green M, et al
    The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors.
    Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05717.
    >> Share

  571. PLYM A, Johansson ALV, Bower H, Wennstig AK, et al
    Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study.
    Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05720.
    >> Share

  572. RAMIREZ-EXPOSITO MJ, Martinez-Martos JM, Duenas-Rodriguez B, Navarro-Cecilia J, et al
    Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins.
    Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05723.
    >> Share

  573. LEON-FERRE RA, Perez EA, Hillman DW, Bueno C, et al
    N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jun 5. pii: 10.1007/s10549-020-05709.
    >> Share

  574. BUONO G, Crispo A, Giuliano M, De Angelis C, et al
    Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
    Breast Cancer Res Treat. 2020 Jun 4. pii: 10.1007/s10549-020-05701.
    >> Share

  575. KRAJNAK S, Schnatz C, Almstedt K, Brenner W, et al
    Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.
    Breast Cancer Res Treat. 2020 Jun 3. pii: 10.1007/s10549-020-05711.
    >> Share

  576. TREWIN CB, Johansson ALV, Hjerkind KV, Strand BH, et al
    Stage-specific survival has improved for young breast cancer patients since 2000: but not equally.
    Breast Cancer Res Treat. 2020 Jun 3. pii: 10.1007/s10549-020-05698.
    >> Share

  577. ALTER BP, Best AF
    Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2020 Jun 2. pii: 10.1007/s10549-020-05710.
    >> Share

  578. REINHORN D, Yerushalmi R, Moore A, Desnoyers A, et al
    Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Jun 1. pii: 10.1007/s10549-020-05715.
    >> Share

  579. BERNSTEIN-MOLHO R, Friedman E, Kedar I, Laitman Y, et al
    Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
    Breast Cancer Res Treat. 2020;181:445-453.
    >> Share

  580. NOORDMAN PCW, Klioueva NM, Weimann MN, Borgstein PJ, et al
    Phyllodes tumors of the breast: a retrospective analysis of 57 cases.
    Breast Cancer Res Treat. 2020;181:361-367.
    >> Share

  581. DOLEN U, Thornton M, Tenenbaum MM, Aripoli A, et al
    A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction.
    Breast Cancer Res Treat. 2020;181:611-621.
    >> Share

  582. BIJKERK E, van Kuijk SMJ, Lataster A, van der Hulst RRWJ, et al
    Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation.
    Breast Cancer Res Treat. 2020;181:599-610.
    >> Share

  583. JIA M, Lin X, Zhou X, Yan H, et al
    Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts.
    Breast Cancer Res Treat. 2020;181:589-597.
    >> Share

  584. SHEN T, Nitta H, Wei L, Parwani AV, et al
    HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas.
    Breast Cancer Res Treat. 2020;181:519-527.
    >> Share

  585. OBDEIJN IM, Mann RM, Loo CCE, Lobbes M, et al
    The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2020;181:581-588.
    >> Share

    May 2020
  586. MIYASHITA H, Cruz C, Malamud S
    Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
    Breast Cancer Res Treat. 2020 May 30. pii: 10.1007/s10549-020-05712.
    >> Share

  587. WU AH, Tseng C, Vigen C, Yu Y, et al
    Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05702.
    >> Share

  588. WARD MC, Vicini F, Al-Hilli Z, Chadha M, et al
    Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05706.
    >> Share

  589. CHO H, Lee S, Sim SH, Park IH, et al
    Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05703.
    >> Share

  590. ONG CT, Ren Y, Thomas SM, Stashko I, et al
    Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05700.
    >> Share

  591. MUSTONEN L, Vollert J, Rice ASC, Kalso E, et al
    Sensory profiles in women with neuropathic pain after breast cancer surgery.
    Breast Cancer Res Treat. 2020 May 27. pii: 10.1007/s10549-020-05681.
    >> Share

  592. BEITSCH P, Whitworth P, Patel R
    Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID19 pandemic. The COVID19 pandemic breast cancer consortium".
    Breast Cancer Res Treat. 2020 May 26. pii: 10.1007/s10549-020-05694.
    >> Share

  593. HA SM, Chang JM, Lee SH, Kim ES, et al
    Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2020 May 23. pii: 10.1007/s10549-020-05697.
    >> Share

  594. DELGADO-RAMOS GM, Nasir SS, Wang J, Schwartzberg LS, et al
    Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women.
    Breast Cancer Res Treat. 2020 May 23. pii: 10.1007/s10549-020-05684.
    >> Share

  595. JOSEPH C, Alsaleem M, Orah N, Narasimha PL, et al
    Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
    Breast Cancer Res Treat. 2020 May 22. pii: 10.1007/s10549-020-05670.
    >> Share

  596. SCATENA C, Scarpitta R, Innocenti L, Miccoli M, et al
    Androgen receptor expression inversely correlates with histological grade and N stage in ER(+)/PgR(low) male breast cancer.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05682.
    >> Share

  597. MEJDAHL MK, Wohlfahrt J, Holm M, Knoop AS, et al
    Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05689.
    >> Share

  598. DAHN H, Wilke D, Walsh G, Pignol JP, et al
    Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05691.
    >> Share

  599. WATANABE J
    Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05695.
    >> Share

  600. OMILIAN AR, Wei L, Hong CC, Bandera EV, et al
    Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05693.
    >> Share

  601. O'SHAUGHNESSY J
    Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05674.
    >> Share

  602. LOFTEROD T, Frydenberg H, Flote V, Eggen AE, et al
    Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05679.
    >> Share

  603. DEUTSCH TM, Riethdorf S, Fremd C, Feisst M, et al
    HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05687.
    >> Share

  604. ALMSTEDT K, Mendoza S, Otto M, Battista MJ, et al
    EndoPredict((R)) in early hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05688.
    >> Share

  605. TOMAO F, Verrico M, Tomao S
    Fertility and reproduction in breast cancer patients.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05676.
    >> Share

  606. ZHONG Y, Xu Y, Zhou Y, Mao F, et al
    Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.
    Breast Cancer Res Treat. 2020 May 19. pii: 10.1007/s10549-020-05686.
    >> Share

  607. LI Y, Qin J, Wu J, Dai X, et al
    High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
    Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05671.
    >> Share

  608. BACH L, Kostev K, Schiffmann L, Kalder M, et al
    Association between thyroid gland diseases and breast cancer: a case-control study.
    Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05675.
    >> Share

  609. KOUMARIANOU A, Makrantonakis P, Zagouri F, Papadimitriou C, et al
    ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05677.
    >> Share

  610. LEE HB, Han W, Kim SY, Cho N, et al
    Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05678.
    >> Share

  611. HAO Y, Xu B, Yan Q, Zhou M, et al
    Long-term excess body fat in adulthood and the risk of pre- and postmenopausal breast cancer in Chinese women.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05685.
    >> Share

  612. ZHANG LY, Zhang YQ, Zeng YZ, Zhu JL, et al
    TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05673.
    >> Share

  613. SILVA CL, Perestrelo R, Sousa-Ferreira I, Capelinha F, et al
    Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05672.
    >> Share

  614. KALINSKY K, Accordino MK, Hosi K, Hawley JE, et al
    Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City.
    Breast Cancer Res Treat. 2020 May 14:1-4. doi: 10.1007/s10549-020-05667.
    >> Share

  615. KALINSKY K, Accordino MK, Hosi K, Hawley JE, et al
    Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City.
    Breast Cancer Res Treat. 2020 May 14. pii: 10.1007/s10549-020-05667.
    >> Share

  616. ZHOU L, Chen B, Sheng L, Turner A, et al
    The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis.
    Breast Cancer Res Treat. 2020 May 13. pii: 10.1007/s10549-020-05669.
    >> Share

  617. ROJAS KE, Manasseh DM, Rojas M, Mattocks A, et al
    The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer.
    Breast Cancer Res Treat. 2020 May 12. pii: 10.1007/s10549-020-05666.
    >> Share

  618. SAITO T, Ono R, Kono S, Asano M, et al
    Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
    Breast Cancer Res Treat. 2020 May 12. pii: 10.1007/s10549-020-05668.
    >> Share

  619. DU F, Wang W, Wang Y, Li M, et al
    Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 May 11. pii: 10.1007/s10549-020-05648.
    >> Share

  620. EZRATTY C, Vang S, Brown J, Margolies LR, et al
    Racial/ethnic differences in supplemental imaging for breast cancer screening in women with dense breasts.
    Breast Cancer Res Treat. 2020 May 11. pii: 10.1007/s10549-020-05652.
    >> Share

  621. UMAMAHESWARAN G, Kadambari D, Muthuvel SK, Kalaivani S, et al
    Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    Breast Cancer Res Treat. 2020 May 8. pii: 10.1007/s10549-020-05656.
    >> Share

  622. EDMAN KESSLER L, Sigfridsson J, Hatzidaki D, Bergh J, et al
    Chemotherapy use near the end-of-life in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 7. pii: 10.1007/s10549-020-05663.
    >> Share

  623. HEYDON-WHITE A, Suami H, Boyages J, Koelmeyer L, et al
    Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05661.
    >> Share

  624. O'TOOLE SA, Spillane C, Huang Y, Fitzgerald MC, et al
    Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05658.
    >> Share

  625. NINO DE GUZMAN E, Song Y, Alonso-Coello P, Canelo-Aybar C, et al
    Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05657.
    >> Share

  626. O'DONNELL PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, et al
    Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05603.
    >> Share

  627. WANG C, Mu Z, Ye Z, Zhang Z, et al
    Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
    Breast Cancer Res Treat. 2020 May 4. pii: 10.1007/s10549-020-05662.
    >> Share

  628. WANG RX, Ji P, Gong Y, Shao ZM, et al
    Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.
    Breast Cancer Res Treat. 2020 May 2. pii: 10.1007/s10549-020-05660.
    >> Share

  629. STOVGAARD ES, Bokharaey M, List-Jensen K, Roslind A, et al
    PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
    Breast Cancer Res Treat. 2020 May 2. pii: 10.1007/s10549-020-05655.
    >> Share

  630. MUKHTAR RA, Krings G, Chen YY, Mamounas ME, et al
    Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Breast Cancer Res Treat. 2020;181:23-29.
    >> Share

  631. DO WL, Conneely K, Gabram-Mendola S, Krishnamurti U, et al
    Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?
    Breast Cancer Res Treat. 2020;181:135-144.
    >> Share

  632. PURRINGTON KS, Gorski D, Simon MS, Hastert TA, et al
    Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
    Breast Cancer Res Treat. 2020;181:145-154.
    >> Share

  633. OLIVERI S, Ongaro G, Durosini I, Curigliano G, et al
    Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support.
    Breast Cancer Res Treat. 2020;181:221-224.
    >> Share

  634. LIU W, Li W, Li Z, Shi L, et al
    Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma.
    Breast Cancer Res Treat. 2020;181:127-134.
    >> Share

  635. FRASSON AL, Lichtenfels M, de Souza AAB, Vollbrecht B, et al
    Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    Breast Cancer Res Treat. 2020;181:69-75.
    >> Share

    April 2020
  636. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos-Calderon C, Perez-Gomez B, et al
    Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study.
    Breast Cancer Res Treat. 2020 Apr 30. pii: 10.1007/s10549-020-05600.
    >> Share

  637. SOARES LR, Rosa VDL, Freitas-Junior R
    Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life.
    Breast Cancer Res Treat. 2020 Apr 29. pii: 10.1007/s10549-020-05659.
    >> Share

  638. ALJOHANI AI, Joseph C, Kurozumi S, Mohammed OJ, et al
    Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Apr 29. pii: 10.1007/s10549-020-05646.
    >> Share

  639. TROGDON JG, Baggett CD, Gogate A, Reeder-Hayes KE, et al
    Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
    Breast Cancer Res Treat. 2020 Apr 28. pii: 10.1007/s10549-020-05654.
    >> Share

  640. HUNT BG, Wicker CA, Bourn JR, Lower EE, et al
    MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 27. pii: 10.1007/s10549-020-05653.
    >> Share

  641. ALTUNDAG K
    Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?
    Breast Cancer Res Treat. 2020 Apr 27. pii: 10.1007/s10549-020-05649.
    >> Share

  642. DIETZ JR, Moran MS, Isakoff SJ, Kurtzman SH, et al
    Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
    Breast Cancer Res Treat. 2020 Apr 24. pii: 10.1007/s10549-020-05644.
    >> Share

  643. YOO TK, Kang BJ, Kim SH, Song BJ, et al
    Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Breast Cancer Res Treat. 2020 Apr 23. pii: 10.1007/s10549-020-05636.
    >> Share

  644. GOTTSCHAU M, Kjaer SK, Settnes A, Aalborg GL, et al
    Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study.
    Breast Cancer Res Treat. 2020 Apr 23. pii: 10.1007/s10549-020-05628.
    >> Share

  645. BROWN TA 2ND, Mittendorf EA, Hale DF, Myers JW 3rd, et al
    Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
    Breast Cancer Res Treat. 2020 Apr 22. pii: 10.1007/s10549-020-05638.
    >> Share

  646. JACENE HA, DiPiro PJ, Bellon J, Hu J, et al
    Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05631.
    >> Share

  647. MIYASHITA H, Satoi S, Kuno T, Cruz C, et al
    Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05640.
    >> Share

  648. ZENG C, Guo X, Wen W, Shi J, et al
    Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05643.
    >> Share

  649. MALOUFF TD, Mahajan A, Mutter RW, Krishnan S, et al
    Carbon ion radiation therapy in breast cancer: a new frontier.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05641.
    >> Share

  650. KAWACHI A, Yamashita S, Okochi-Takada E, Hirakawa A, et al
    BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    Breast Cancer Res Treat. 2020 Apr 20. pii: 10.1007/s10549-020-05647.
    >> Share

  651. KWAK A, Jacobs J, Haggett D, Jimenez R, et al
    Evaluation and management of insomnia in women with breast cancer.
    Breast Cancer Res Treat. 2020 Apr 20. pii: 10.1007/s10549-020-05635.
    >> Share

  652. JING J, Feng R, Zhang X, Li M, et al
    Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China.
    Breast Cancer Res Treat. 2020 Apr 18. pii: 10.1007/s10549-020-05632.
    >> Share

  653. HERSHMAN DL, Till C, Wright JD, Accordino M, et al
    Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials.
    Breast Cancer Res Treat. 2020 Apr 18. pii: 10.1007/s10549-020-05634.
    >> Share

  654. HAAS CB, Nekhlyudov L, Lee JM, Javid SH, et al
    Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2020 Apr 17. pii: 10.1007/s10549-020-05637.
    >> Share

  655. JORGENSEN CLT, Forsare C, Bendahl PO, Falck AK, et al
    Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
    Breast Cancer Res Treat. 2020 Apr 16. pii: 10.1007/s10549-020-05627.
    >> Share

  656. ASAOKA M, Patnaik SK, Zhang F, Ishikawa T, et al
    Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response.
    Breast Cancer Res Treat. 2020 Apr 13. pii: 10.1007/s10549-020-05630.
    >> Share

  657. GIARDIELLO D, Hauptmann M, Steyerberg EW, Adank MA, et al
    Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.
    Breast Cancer Res Treat. 2020 Apr 11. pii: 10.1007/s10549-020-05611.
    >> Share

  658. LAWS MJ, Ziegler Y, Shahoei SH, Dey P, et al
    Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
    Breast Cancer Res Treat. 2020 Apr 10. pii: 10.1007/s10549-020-05629.
    >> Share

  659. GREENWELL K, Hussain L, Lee D, Bramlage M, et al
    Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
    Breast Cancer Res Treat. 2020 Apr 10. pii: 10.1007/s10549-020-05599.
    >> Share

  660. DRULLINSKY PR, Hurvitz SA
    Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
    Breast Cancer Res Treat. 2020 Apr 9. pii: 10.1007/s10549-020-05618.
    >> Share

  661. RIBI K, Luo W, Walley BA, Burstein HJ, et al
    Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2020 Apr 9. pii: 10.1007/s10549-020-05622.
    >> Share

  662. HIRAKATA T, Fujii T, Kurozumi S, Katayama A, et al
    FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05619.
    >> Share

  663. PINERO-MADRONA A, Ripoll-Orts F, Sanchez-Mendez JI, Chaves-Benito A, et al
    External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05623.
    >> Share

  664. ALEIXO GFP, Deal AM, Nyrop KA, Muss HB, et al
    Association of body composition with function in women with early breast cancer.
    Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05624.
    >> Share

  665. WATANABE J, Saito M, Horimoto Y, Nakamoto S, et al
    A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
    Breast Cancer Res Treat. 2020 Apr 5. pii: 10.1007/s10549-020-05626.
    >> Share

  666. HIRAI T, Nemoto A, Ito Y, Matsuura M, et al
    Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05615.
    >> Share

  667. LE AN, Harton J, Desai H, Powers J, et al
    Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
    Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05612.
    >> Share

  668. FRANZOI MA, Vandeputte C, Eiger D, Caparica R, et al
    Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
    Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05617.
    >> Share

  669. PAN L, Chen X, Fu S, Yu W, et al
    LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05613.
    >> Share

  670. SUNDELIN EIO, Al-Suliman N, Vahl P, Vendelbo M, et al
    Metformin is distributed to tumor tissue in breast cancer patients in vivo: A (11)C-metformin PET/CT study.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05621.
    >> Share

  671. DENYS H, Martinez-Mena CL, Martens MT, D'Hondt RG, et al
    Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05604.
    >> Share

  672. LEI YY, Ho SC, Cheng A, Kwok C, et al
    The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 1. pii: 10.1007/s10549-020-05616.
    >> Share

  673. NEVEN P, Froyman W, Timmerman S, Timmerman D, et al
    Uterine ultrasound and endometrial biopsy in tamoxifen users.
    Breast Cancer Res Treat. 2020;180:833-834.
    >> Share

  674. ALTUNDAG K
    HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology.
    Breast Cancer Res Treat. 2020;180:829.
    >> Share

  675. SUNAGUCHI N, Shimao D, Yuasa T, Ichihara S, et al
    Three-dimensional microanatomy of human nipple visualized by X-ray dark-field computed tomography.
    Breast Cancer Res Treat. 2020;180:397-405.
    >> Share

  676. KATZ MS, McCall L, Ballman K, Jagsi R, et al
    Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations.
    Breast Cancer Res Treat. 2020;180:429-436.
    >> Share

  677. SEOW DYB, Yeong JPS, Lim JX, Chia N, et al
    Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.
    Breast Cancer Res Treat. 2020;180:369-377.
    >> Share

  678. STUMPF CC, Zucatto AE, Cavalheiro JAC, de Melo MP, et al
    Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery.
    Breast Cancer Res Treat. 2020;180:301-309.
    >> Share

  679. LI AC, Zhao J, Zhao C, Ma Z, et al
    Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Breast Cancer Res Treat. 2020;180:321-329.
    >> Share

  680. JENNARO TS, Fang F, Kidwell KM, Smith EML, et al
    Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
    Breast Cancer Res Treat. 2020;180:707-714.
    >> Share

  681. YARDLEY DA, Peacock N, Daniel B, Anz B, et al
    Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020;180:647-655.
    >> Share

    March 2020
  682. GONG IY, Yan AT, Earle CC, Trudeau ME, et al
    Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05614.
    >> Share

  683. VRIENS IJH, Ter Welle-Butalid EM, de Boer M, de Die-Smulders CEM, et al
    Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05598.
    >> Share

  684. BHATTACHARJEE A, Rajendra J, Dikshit R, Dutt S, et al
    HER2 borderline is a negative prognostic factor for primary malignant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05608.
    >> Share

  685. BRANDBERG Y, Johansson H, Hellstrom M, Gnant M, et al
    Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05602.
    >> Share

  686. JOBSEN JJ, Struikmans H, van der Palen J, Siemerink E, et al
    The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer.
    Breast Cancer Res Treat. 2020 Mar 30. pii: 10.1007/s10549-020-05610.
    >> Share

  687. EL ANSARI R, Alfarsi L, Craze ML, Masisi BK, et al
    The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05586.
    >> Share

  688. GENNARI A, Foca F, Zamarchi R, Rocca A, et al
    Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05596.
    >> Share

  689. VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
    Behavior of metastatic breast cancer according to subtype.
    Breast Cancer Res Treat. 2020 Mar 19. pii: 10.1007/s10549-020-05597.
    >> Share

  690. PANZIRONI G, Moffa G, Galati F, Marzocca F, et al
    Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner.
    Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05592.
    >> Share

  691. HASSETT MJ, Li H, Burstein HJ, Punglia RS, et al
    Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05587.
    >> Share

  692. SIMONS JM, Koppert LB, Luiten EJT, van der Pol CC, et al
    De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05589.
    >> Share

  693. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Correction to: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05594.
    >> Share

  694. MA G, Zhang B, Xu J
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05593.
    >> Share

  695. YUAN C, Xie Z, Bian J, Huo J, et al
    Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
    Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05591.
    >> Share

  696. CROLLEY VE, Marashi H, Rawther S, Sirohi B, et al
    The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05578.
    >> Share

  697. ISHIGURO H, Masuda N, Sato N, Higaki K, et al
    A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05590.
    >> Share

  698. O'SULLIVAN CC, Irshad S, Wang Z, Tang Z, et al
    Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period.
    Breast Cancer Res Treat. 2020 Mar 11. pii: 10.1007/s10549-020-05585.
    >> Share

  699. IWASE M, Ando M, Aogi K, Aruga T, et al
    Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Mar 5. pii: 10.1007/s10549-020-05580.
    >> Share

  700. ANDREANO KJ, Wardell SE, Baker JG, Desautels TK, et al
    G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 4. pii: 10.1007/s10549-020-05575.
    >> Share

  701. TAYLOR LJ, Steiman JS, Anderson B, Schumacher JR, et al
    Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?
    Breast Cancer Res Treat. 2020 Mar 3. pii: 10.1007/s10549-020-05579.
    >> Share

  702. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05567.
    >> Share

  703. MASUDA T, Fujimoto H, Teranaka R, Kuroda M, et al
    Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05581.
    >> Share

    February 2020
  704. JEON YW, Bang HW, Suh YJ, Kim G, et al
    The long-term effect of age on cardiovascular disease in patients with breast cancer who received chemotherapy.
    Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05568.
    >> Share

  705. PARACHA N, Reyes A, Dieras V, Krop I, et al
    Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analys
    Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05577.
    >> Share

  706. ROJAS-LIMA E, Gamboa-Loira B, Cebrian ME, Rothenberg SJ, et al
    A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
    Breast Cancer Res Treat. 2020 Feb 22. pii: 10.1007/s10549-020-05562.
    >> Share

  707. LAMBERT-COTE L, Bouhnik AD, Bendiane MK, Berenger C, et al
    Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Breast Cancer Res Treat. 2020 Feb 21. pii: 10.1007/s10549-020-05549.
    >> Share

  708. PAN K, Ray RM, Cauley JA, Shadyab AH, et al
    Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05576.
    >> Share

  709. KIM M, Kim H, Ahn SH, Tabatabaie V, et al
    Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05566.
    >> Share

  710. CHEN L, Fu F, Huang M, Lv J, et al
    The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
    Breast Cancer Res Treat. 2020 Feb 18. pii: 10.1007/s10549-020-05573.
    >> Share

  711. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Feb 17. pii: 10.1007/s10549-020-05564.
    >> Share

  712. YUNG R, Ray RM, Roth J, Johnson L, et al
    The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.
    Breast Cancer Res Treat. 2020 Feb 15. pii: 10.1007/s10549-020-05572.
    >> Share

  713. CORONA SP, Bortul M, Scomersi S, Bigal C, et al
    Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05565.
    >> Share

  714. ZHANG L, Hsieh MC, Petkov V, Yu Q, et al
    Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05557.
    >> Share

  715. CHEN Z, Xu L, Shi W, Zeng F, et al
    Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017.
    Breast Cancer Res Treat. 2020 Feb 13. pii: 10.1007/s10549-020-05561.
    >> Share

  716. RYPENS C, Marsan M, Van Berckelaer C, Billiet C, et al
    Inflammatory breast cancer cells are characterized by abrogated TGFbeta1-dependent cell motility and SMAD3 activity.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05571.
    >> Share

  717. RACHNER TD, Gobel A, Hoffmann O, Erdmann K, et al
    High serum levels of periostin are associated with a poor survival in breast cancer.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05570.
    >> Share

  718. SARMIENTO S, McColl M, Musavi L, Gani F, et al
    Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05556.
    >> Share

  719. SORSCHER S, Ansley K, Delaney SD, Ramkissoon S, et al
    The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05569.
    >> Share

  720. SUN X, Wang XE, Zhang ZP, Shi ZQ, et al
    Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05559.
    >> Share

  721. YU M, Chen Y, Wang Z, Ding X, et al
    pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05560.
    >> Share

  722. MILLS MN, Figura NB, Arrington JA, Yu HM, et al
    Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05552.
    >> Share

  723. GUO S, Zhang C, Mottamal M, Hossain A, et al
    GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05558.
    >> Share

  724. JOOB B, Wiwanitkit V
    CYP24A1 polymorphisms and breast cancer risk.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05553.
    >> Share


  725. UK Interdisciplinary Breast Cancer Symposium 2020.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-019-05514.
    >> Share

  726. PAREKH VS, Jacobs MA
    Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05533.
    >> Share

  727. KIM HS, Yoo TK, Park WC, Chae BJ, et al
    The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05550.
    >> Share

  728. ZHU J, Wang F, Shi L, Cai H, et al
    Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05541.
    >> Share

  729. SHIBAYAMA T, Low SK, Ono M, Kobayashi T, et al
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-019-05512.
    >> Share

  730. DICORPO D, Tiwari A, Tang R, Griffin M, et al
    The role of Micro-CT in imaging breast cancer specimens.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05547.
    >> Share

  731. LI M, Xiong Y, Liao C, He Y, et al
    Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2020 Feb 1. pii: 10.1007/s10549-020-05551.
    >> Share

  732. ZDRAVKOVIC D, Granic M, Crnokrak B
    Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery?
    Breast Cancer Res Treat. 2020;179:765.
    >> Share

  733. ALTUNDAG K
    Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?
    Breast Cancer Res Treat. 2020;179:763.
    >> Share

  734. TRACEY N, Creedon H, Kemp AJ, Culley J, et al
    HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Breast Cancer Res Treat. 2020;179:543-555.
    >> Share

  735. MEIER DR, Girtman MA, Lofgren KA, Kenny PA, et al
    Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.
    Breast Cancer Res Treat. 2020;179:653-660.
    >> Share

  736. KYKER-SNOWMAN K, Hughes RM, Yankaskas CL, Cravero K, et al
    TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
    Breast Cancer Res Treat. 2020;179:631-642.
    >> Share

  737. BROWNE JL, Casas L, Santandreu G, Rodriguez I, et al
    Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology.
    Breast Cancer Res Treat. 2020;179:755-762.
    >> Share

  738. LOOK HONG N, Wright FC, Semple M, Nicolae AM, et al
    Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions.
    Breast Cancer Res Treat. 2020;179:671-676.
    >> Share

  739. PIROT F, Chaltiel D, Ben Lakhdar A, Mathieu MC, et al
    Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? A series of 39 patients.
    Breast Cancer Res Treat. 2020;180:87-95.
    >> Share

  740. ADHIKARY S, Hoskin TL, Stallings-Mann ML, Arshad M, et al
    Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease.
    Breast Cancer Res Treat. 2020;180:55-61.
    >> Share

    January 2020
  741. LINNENBRINGER E, Geronimus AT, Davis KL, Bound J, et al
    Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women.
    Breast Cancer Res Treat. 2020 Jan 30. pii: 10.1007/s10549-020-05545.
    >> Share

  742. QIAN XL, Xu P, Zhang YQ, Song YM, et al
    Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jan 29. pii: 10.1007/s10549-020-05540.
    >> Share

  743. RAINVILLE I, Hatcher S, Rosenthal E, Larson K, et al
    High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Breast Cancer Res Treat. 2020 Jan 28. pii: 10.1007/s10549-020-05543.
    >> Share

  744. ROSE M, Svensson H, Handler J, Hoyer U, et al
    Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05544.
    >> Share

  745. DE BONIFACE J, Ahlgren J, Andersson Y, Bergkvist L, et al
    The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05537.
    >> Share

  746. KANAI A, McNamara KM, Iwabuchi E, Miki Y, et al
    Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05523.
    >> Share

  747. MOUSLIM MC, Johnson RM, Dean LT
    Healthcare system distrust and the breast cancer continuum of care.
    Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05538.
    >> Share

  748. ZENG F, Heng J, Guo X, Wang Y, et al
    The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
    Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05536.
    >> Share

  749. PLICHTA JK, Thomas SM, Vernon R, Fayanju OM, et al
    Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.
    Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05542.
    >> Share

  750. FERRARIS C, Ballestra B, Listorti C, Cappelletti V, et al
    Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen.
    Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05534.
    >> Share

  751. LEE C, Check DK, Manace Brenman L, Kushi LH, et al
    Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Breast Cancer Res Treat. 2020 Jan 23. pii: 10.1007/s10549-020-05539.
    >> Share

  752. LI J, Fu F, Yu L, Huang M, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05528.
    >> Share

  753. BANSOD S, Desai R
    Nationwide prevalence and trends of acute cardiovascular and cerebrovascular events among adult breast cancer survivors with a history of radiation therapy.
    Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05535.
    >> Share

  754. FAYANJU OM, Ren Y, Greenup RA, Plichta JK, et al
    Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
    Breast Cancer Res Treat. 2020 Jan 20. pii: 10.1007/s10549-020-05529.
    >> Share

  755. HULSBERGEN AFC, Cho LD, Mammi M, Lamba N, et al
    Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.
    Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05531.
    >> Share

  756. MASUDA N, Ohtani S, Takano T, Inoue K, et al
    A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05524.
    >> Share

  757. KLAESTAD E, Opdahl S, Engstrom MJ, Ytterhus B, et al
    MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05532.
    >> Share

  758. YE ZJ, Zhang Z, Zhang XY, Tang Y, et al
    Effectiveness of adjuvant supportive-expressive group therapy for breast cancer.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05526.
    >> Share

  759. GARCIA X, Elia A, Galizzi L, May M, et al
    Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05527.
    >> Share

  760. LOPEZ G, Fusco N
    RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05530.
    >> Share

  761. ROTILI A, Trimboli RM, Penco S, Pesapane F, et al
    Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05519.
    >> Share

  762. BJERKESET E, Rohrl K, Schou-Bredal I
    Symptom cluster of pain, fatigue, and psychological distress in breast cancer survivors: prevalence and characteristics.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-020-05522.
    >> Share

  763. TADROS AB, Moo TA, Stempel M, Zabor EC, et al
    Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05520.
    >> Share

  764. YAO S, Laurent CA, Roh JM, Lo J, et al
    Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
    Breast Cancer Res Treat. 2020 Jan 7. pii: 10.1007/s10549-019-05518.
    >> Share

  765. WIJAYABAHU AT, Egan KM, Yaghjyan L
    Uterine cancer in breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05516.
    >> Share

  766. KIM SS, Lee MH, Lee MO
    Histone methyltransferases regulate the transcriptional expression of ERalpha and the proliferation of tamoxifen-resistant breast cancer cells.
    Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05517.
    >> Share

  767. TYNAN M, Peshkin BN, Isaacs C, Willey S, et al
    Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2020 Jan 1. pii: 10.1007/s10549-019-05515.
    >> Share

  768. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Authors' reply to the comment "Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism".
    Breast Cancer Res Treat. 2020;179:519-520.
    >> Share

  769. GRADISHAR B
    Editorial.
    Breast Cancer Res Treat. 2020;179:1.
    >> Share

  770. DE AZAMBUJA E, Ponde N, Procter M, Rastogi P, et al
    A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
    Breast Cancer Res Treat. 2020;179:161-171.
    >> Share

  771. HAWSE JR, Carter JM, Aspros KGM, Bruinsma ES, et al
    Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.
    Breast Cancer Res Treat. 2020;179:241-249.
    >> Share

  772. MITRA D, Bhattacharyya S, Alam N, Sen S, et al
    Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Breast Cancer Res Treat. 2020;179:359-370.
    >> Share

  773. MERRILL NM, Lachacz EJ, Vandecan NM, Ulintz PJ, et al
    Molecular determinants of drug response in TNBC cell lines.
    Breast Cancer Res Treat. 2020;179:337-347.
    >> Share

  774. FUNK A, Heil J, Harcos A, Gomez C, et al
    Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery.
    Breast Cancer Res Treat. 2020;179:425-433.
    >> Share

  775. MULLOOLY M, Withrow DR, Curtis RE, Fan S, et al
    Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study.
    Breast Cancer Res Treat. 2020;179:445-457.
    >> Share

  776. BERRY DL, Blonquist TM, Halpenny B, Hong F, et al
    The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study.
    Breast Cancer Res Treat. 2020;179:377-385.
    >> Share

  777. NEALON KP, Sobti N, Gadd M, Specht M, et al
    Assessing the additional surgical risk of contralateral prophylactic mastectomy and immediate breast implant reconstruction.
    Breast Cancer Res Treat. 2020;179:255-265.
    >> Share

    December 2019
  778. LI Y, Zhou Y, Mao F, Lin Y, et al
    Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Breast Cancer Res Treat. 2019 Dec 21. pii: 10.1007/s10549-019-05513.
    >> Share

  779. CHEN HL, Du L, Li XM
    Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 19. pii: 10.1007/s10549-019-05510.
    >> Share

  780. HEUBLEIN S, Egger M, Zhu J, Berger L, et al
    Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 11. pii: 10.1007/s10549-019-05503.
    >> Share

  781. KIM MH, Kim GM, Kim JH, Kim JY, et al
    Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Breast Cancer Res Treat. 2019 Dec 6. pii: 10.1007/s10549-019-05505.
    >> Share

  782. YASRI S, Wiwanitkit V
    Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism.
    Breast Cancer Res Treat. 2019;178:713.
    >> Share

    November 2019
  783. HII LW, Chung FF, Soo JS, Tan BS, et al
    Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
    Breast Cancer Res Treat. 2019 Nov 29. pii: 10.1007/s10549-019-05504.
    >> Share

  784. CLAESSENS AKM, Timman R, Busschbach JJ, Bouma JM, et al
    The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
    Breast Cancer Res Treat. 2019 Nov 28. pii: 10.1007/s10549-019-05495.
    >> Share

  785. ANDERSEN JLM, Hansen L, Thomsen BLR, Christiansen LR, et al
    Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort.
    Breast Cancer Res Treat. 2019 Nov 26. pii: 10.1007/s10549-019-05497.
    >> Share

  786. WU Y, Ouyang T, Li J, Wang T, et al
    Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Nov 25. pii: 10.1007/s10549-019-05483.
    >> Share

  787. KULIGINA ES, Sokolenko AP, Bizin IV, Romanko AA, et al
    Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39.
    Breast Cancer Res Treat. 2019 Nov 21. pii: 10.1007/s10549-019-05492.
    >> Share

  788. ALMEIDA M, Soares M, Ramalhinho AC, Moutinho JF, et al
    The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.
    Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05494.
    >> Share